

Appendix A  
U.S. Patent No. 10/551,475

Claims (Presented in February 17, 2009 Amendment)	Support in Present Application <sup>1</sup>	Support in Priority UK Application (UK patent 0307559.5)
<p>47. (currently amended). Library comprising a plurality of tagged ligands of formula I</p> $(\text{Lig } J_L)_m \text{ L } (J_T \text{ Tag})_m (J_T \text{ L } (J_L \text{ Lig})_m)_p$ <p>and salts thereof wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers</p> <p>comprising one or a plurality of same or different ligand moieties Lig each linked to one or a plurality of same or different tag moieties Tag via same or different linker moieties L and same or different linking site or linking functionality <math>J_T</math> and <math>J_L</math></p> <p>wherein Lig comprises a GPCR ligand, an inhibitor of an intracellular enzyme or a substrate or inhibitor of a drug transporter;</p> <p>L is selected from a <u>single or double bond</u>, -O-, -S-, amine, COO-, amide, -NN-hydrazine, and saturated or unsaturated, substituted or unsubstituted C<sub>1-600</sub> branched</p>	<p>[0014]</p> <p>[0173]</p> <p>[0014]</p> <p>[0045]</p>	

<sup>1</sup> Support for present application is shown by citations to paragraph numbers in U.S. Publication No. 2006/0122045 A1

<p>or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any C<sub>1-20</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amino, hydrazine, oxo, cyano and carbonyl and combinations thereof, and L may be monomeric, oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300;</p> <p>Tag is any tagging substrate;</p> <p>m are each independently selected from a whole number integer from 1 to 3;</p> <p>p is 0 to 3</p> <p>wherein one or more of each -Tag in one or more or each library compound is a fluorophore entity</p> <p>-Fl, whereby the library comprises compounds of which one or more or all of which are of formula</p> <p><math>\text{I}^p</math></p> <p><math>(\text{L}_1\text{g}_1)_m (\text{I}^p \text{Fl})_m (\text{I}^p \text{L} (\text{I}_2 \text{L}_1\text{g}_2)_m)_p</math></p> <p>characterised in that linking is at same or different linking sites in compounds comprising different Lig, L<sub>1</sub>, L, I<sub>2</sub> and/or -Tag and is at different linking sites in compounds comprising same Lig, L<sub>1</sub>, L, I<sub>2</sub> and/or -Tag</p> <p>wherein the or each Fl is selected from a red, near ir or blue dye with the proviso that when Lig is</p> <p>CGP12177 and L<sub>1</sub> is 1,1,4,4-tetramethyl butylamine C(CH<sub>3</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>NH<sub>2</sub>, Fl is not BODIPY@Fl<sub>2</sub> or when L<sub>1</sub> is C(CH<sub>3</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>NHCSNH<sub>2</sub> then Fl is not FITC, eosin or erythrosin.</p>	<p>[0015]</p> <p>[0016]</p> <p>[0017]</p> <p>[0018]</p> <p>[0027]</p>	
<p>[0016]</p> <p>[0018]</p> <p>[0015]</p>		

<p>48. (withdrawn and currently amended) Library comprising a plurality of tagged ligands of formula I</p>	
<p> <math display="block">(Lig)_m L (I_T Tag)_m (I_T L (I_L Lig))_p</math> </p> <p>and salts thereof wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers</p> <p>comprising one or a plurality of same or different ligand moieties Lig each linked to one or a plurality of same or different tag moieties Tag via same or different linker moieties L and same or different linking site or linking functionality <math>I_T</math> and <math>I_L</math></p> <p>wherein Lig comprises a GPCR ligand, an inhibitor of an intracellular enzyme or a substrate or inhibitor of a drug transporter;</p> <p>L is selected from a <u>single or double bond</u>, -O-, -S-, amine, COO-, amide, -NN- hydrazine, and saturated or unsaturated, substituted or unsubstituted <math>C_{1-600}</math> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any <math>C_{1-20}</math> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amino, hydrazine, oxo, cyano and carbonyl and</p>	<p>[0014]</p> <p>[0173]</p> <p>[0014]</p> <p>[0045]</p>

	<p>combinations thereof, and L may be monomeric, oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300;</p> <p>Tag is any tagging substrate;</p> <p>m are each independently selected from a whole number integer from 1 to 3;</p> <p>p is 0 to 3</p> <p>wherein one or more of each -Tag in one or more or each library compound is a fluorophore entity -Fl, whereby the library comprises compounds of which one or more or all of which are of formula</p> $I^p$ $(LigL)_m L (I^p Fl)_m (I^p L (LigL)_m)_p$ <p>characterised in that linking is at same or different linking sites in compounds comprising different Lig, L, L<sub>1</sub> and/or -Tag and is at different linking sites in compounds comprising same Lig, L, L<sub>1</sub> and/or -Tag.</p> <p>wherein the or each Fl is selected from the following dyes: Texas red™, coumarin and derivatives Cascade Blue™, EVOBlue and fluorescent derivatives thereof, pyrenes and pyridyloxazole derivatives, the cyanine dyes, the dyomics (DY dyes and ATTO dyes) and fluorescent derivatives thereof, the Alexafluor dyes and derivatives, BODIPY dyes including the commercially available Bodipy™ dyes, pyrenes, anthracenes, acridines, fluorescent phycoobiliproteins and their conjugates and fluoresceinated microbeads, and Texas Red derivatives, coupled to amine groups using the isocyanate, succinimidyl ester or dichlorotriazinyl-reactive groups.</p>	<p>[0015]</p> <p>[0016]</p> <p>[0017]</p> <p>[0018]</p> <p>[0027]</p>	
49	(withdrawn and currently amended). Library as claimed in any of Claim 47 wherein each	[0028]	

<p>compound of formula I or I' comprises one of a plurality of fluorophores and/or tags providing a library of differently fluorescently tagged ligands comprising one or a number of different fluorophores optionally of different chemical composition or spectral characteristics; and/or providing a library of differently tagged ligands including at least one fluorescently tagged ligand; [0030]alternatively each compound of formula I or I' comprises one of a plurality of precursor ligands linked each to one or a plurality of different tags providing a library of same or differently tagged ligands of plural ligand type; alternatively each compound of formula I comprises one of a plurality of linkers linking a precursor ligand and at least one Tag at the same or different linking site; alternatively each compound of formula I or I' comprises the same linker linking a precursor ligand and at least one Tag at different linking sites providing a library of differently linked tagged ligands of different conformation or anticipated pharmacology and binding.</p>	
<p>50 (withdrawn). Library as claimed in Claim 47 comprising a plurality of compounds of one or more of formula II to III:</p> <p>II (LigL)<sub>m</sub> L-J<sub>r</sub> TagJ<sub>r</sub> L (J<sub>L</sub> Lig)<sub>m</sub> where each m is as hereinbefore defined and is preferably 1 or 2, more preferably 1</p> <p>III (LigL)<sub>m</sub> L (J<sub>r</sub>T)<sub>m</sub> wherein each m is as hereinbefore defined and is preferably 1 and/or 2, more preferably</p> <p>Lig J<sub>L</sub> - L - J<sub>L</sub> Tag and/or</p> <p>Lig J<sub>L</sub> - L - J<sub>r</sub> Tag and/or</p> <p>Lig J<sub>L</sub> - L - J<sub>r</sub> Tag</p>	<p>[0030]</p>

J <sub>L</sub> Lig	J <sub>T</sub> Tag		
<p>wherein each J<sub>L</sub> and J<sub>T</sub> comprises J as hereinbefore defined and may be same or different and may derive from functionally originally present in Lig or L and Tag or L or a combination thereof, characterised in that linking is at same or different linking sites in compounds comprising different Lig, J<sub>L</sub>, L, J<sub>T</sub> and/or Tag, and is at different linking sites in the case of any two or more compounds comprising identical Lig, J<sub>L</sub>, L, J<sub>T</sub> and/or Tag.</p>			
<p>51 (withdrawn). Library as claimed in Claim 47 including information for each compound of formula I comprised in the Library, relating to the pharmacology for binding to or inhibition of a GPCR receptor or to inhibition of an intracellular cyclic nucleotide phosphodiesterase, or inhibition of or transport by a drug transporter including designation as agonist, antagonist, substrate or inhibitor and measure of affinity or inhibition, enabling quantification of results.</p>	[0036; lines 7-14]		
<p>52 (withdrawn). Library as claimed in Claim 47 wherein a GPCR ligand is selected from any compound which is effective as an agonist or antagonist for an adenosine receptor, a beta-adrenoceptor, a muscarinic receptor, a histamine receptor, an opiate receptor, a cannabinoid receptor, a chemokine receptor, an alpha-adrenoceptor, a GABA receptor, a prostanoïd receptor, a 5-HT (serotonin) receptor, an excitatory aminoacid receptor (glutamate), a dopamine receptor, a protease-activating receptor, a neukinin receptor, an angiotensin receptor, an oxytocin receptor, a</p>	[0021]		

<p>leukotriene receptor, a nucleotide receptor (purines and pyrimidines), a calcium-sensing receptor, a thyroid-stimulating hormone receptor, a neurotensin receptor, a vasopressin receptor, an olfactory receptor, a nucleobase receptor (adenosine), a lysophosphatidic acid receptor, a sphingolipid receptor, a tyramine receptor (trace amines), a free-fatty acid receptor and a cyclic nucleotide receptor; an inhibitor of intracellular enzymes is an inhibitor of cyclic nucleotide phosphodiesterases, and a substrate or inhibitor of a drug transporter is selected from a substrate or inhibitor of an equilibrium based drug transporter or ATP driven pump selected from a catecholamine transporter, a nucleoside transporter, an ATP-binding cassette transporter, a cyclic nucleotide transporter or derivatives or analogues thereof;</p> <p>or wherein Lig is selected from</p> <p>a) xanthine like structures including XAC, theophylline, caffeine, theobromine, dyphylline, enprofylline; or fused biaryl structures including papaverine, dihydroquinilones, clostamide, dipyridamole or vinpocetine; and analogues thereof;</p> <p>b) adenosine like structures including ADAC, NECA and analogues thereof;</p> <p>c) ethanolanine like structures including salmeterol, salbutamol, terbutaline, quiniprenaline, labetalol, sotalol, bambuterol, fenoterol, reproterolol, tulobuterol, clenbuterol and analogues thereof;</p> <p>d) oxypropylamine like structures including CGP12177, propranolol, practolol, acebutolol, betaxolol, ICI 118551, alprenolol, celiprolol (cellectol), metoprolol (betaloc), CGP20712A, atenolol, bisoprolol, misaprolol, carvedilol, bucindolol, esmolol, nadolol, nebivolol, oxprenolol, xamoterol, pindolol, timolol and analogues thereof;</p> <p>e) xanthine like structures including XAC, theophylline, caffeine, theobromine, dyphylline,</p>	<p>[0022]</p> <p>[0023; 1ines</p> <p>9-13]</p>	
<p>a) xanthine like structures including XAC, theophylline, caffeine, theobromine, dyphylline, enprofylline; or fused biaryl structures including papaverine, dihydroquinilones, clostamide, dipyridamole or vinpocetine; and analogues thereof;</p>	<p>[0038]</p> <p>[0039]</p>	
<p>b) adenosine like structures including ADAC, NECA and analogues thereof;</p> <p>c) ethanolanine like structures including salmeterol, salbutamol, terbutaline, quiniprenaline, labetalol, sotalol, bambuterol, fenoterol, reproterolol, tulobuterol, clenbuterol and analogues thereof;</p> <p>d) oxypropylamine like structures including CGP12177, propranolol, practolol, acebutolol, betaxolol, ICI 118551, alprenolol, celiprolol (cellectol), metoprolol (betaloc), CGP20712A, atenolol, bisoprolol, misaprolol, carvedilol, bucindolol, esmolol, nadolol, nebivolol, oxprenolol, xamoterol, pindolol, timolol and analogues thereof;</p> <p>e) xanthine like structures including XAC, theophylline, caffeine, theobromine, dyphylline,</p>	<p>[0040]</p>	

<p>empoylline, sildenafil, EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine), zaprinast, or spiro bicyclic structures including bipyridines, aminone, imidazolines, C1930, dihydropyridazinones, indolan, rolipram, SB207499, or fused biaryl structures including papaverine, dihydroquiniones, ciliostamide, dipyridamole, vinpocetine and analogues thereof.</p>	<p>[0041]</p>	
<p>53 (withdrawn). Library as claimed in Claim 47 wherein <math>J_{\mu m}</math>, <math>L</math>, <math>J_m</math> comprises a mono, di, tri, tetra, penta, or hexa amino, alkylthio, alkoxy, carboxylic acid, and combinations thereof including a mono, di or tri aminoalkylthio, amino alkoxy, alkoxy carboxylic acid or alkoxy amine, mono, di or tri amino methane, amino ethane, thio ethane, ethane, amino acyl, polypeptide, or mono or polyether derivatives including diamine or dithio derivatives, mono or polyethylene glycol di or tri amine or thio;</p> <p>or comprises a mono-, di-, tri- or tetra, penta or hexafunctional linear or branched or cyclic substituted or unsubstituted hydrocarbyl of formula <math>-L-L-</math></p> <p><math>J [A] q_L R_L [A' q_L' J']_p A'' q_L'' J''</math></p> <p>wherein each of <math>J</math> to <math>J''</math> is a linking site or functionality as hereinbefore defined independently selected from a single or double bond, methylene, alkyl, alkene, NR, O, CONR, NRCO, S, CO, NCO, CHHal and P wherein R is H or <math>C_{1-8}</math> alkyl or cycloalkyl or forms part of a cyclic ring with <math>N</math>, Hal is any halogen selected from chlorine, iodine, bromine, and is present in any rational</p>	<p>[0049]</p> <p>[0050]</p>	



<p>location in a group A to A";</p> <p>each of A to A'' is a group selected from -O-, -C(-O)-, C<sub>1-12</sub> alkoxy, alkoyl, cycloalkyl, heterocyclic, alkyl, alkenyl, aryl, arylamide, arylamine, amino, thioalkyl, heteroaryl as hereinbefore defined and combinations thereof, optionally substituted by groups selected independently from C<sub>1-3</sub> alkyl and C<sub>1,5</sub> alkoxy;</p> <p>each of q<sub>1</sub> to q<sub>L</sub>" are independently-selected from 0 or 1 or indicates an oligomeric repeat and is from 2 to 30, or indicates a polymeric repeat unit and is from 31 up to 300.</p> <p>R<sub>L</sub> is a C, N or S atom or is a CR<sub>L</sub>, NR<sub>L</sub>, alkyl, cycloalkyl, heterocyclic, aryl heteroaryl, amine or thio moiety and provides for branching when p is 1 or 2; wherein R<sub>L</sub> is H or C<sub>1-3</sub> alkyl; and</p> <p>p is as hereinbefore defined and is 0, 1 or 2.</p>		
<p>54. (withdrawn). Library as claimed in Claim 47 wherein J<sub>m</sub> L J<sub>m</sub> is of formula</p> <p>J A<sub>qL</sub> R<sub>L</sub> J''</p> <p>wherein each of J and J'' is amine or -O-, A is CH<sub>2</sub>CH<sub>2</sub>O, q<sub>L</sub> is 1-30 or 31 to 300 and R<sub>L</sub> is CH<sub>2</sub>CH<sub>2</sub></p> <p>or of formula</p> <p>J A<sub>qL</sub> R<sub>L</sub>(A'J') J''</p> <p>wherein each of J, J' and J'' independently is amine, -O or a single bond, q<sub>L</sub> is 1, 2 or 3 -30 or 31 to 300 and A is CH<sub>2</sub>CH<sub>2</sub>O or HNCH<sub>2</sub>CO or q<sub>L</sub> is 1 and A is C(O) or (CH<sub>2</sub>)<sub>1-8</sub> or q<sub>L</sub> is 0, R<sub>L</sub> is CH or CH<sub>2</sub>CH<sub>2</sub>, q<sub>L</sub> is 0 or q<sub>L</sub> is 1 and A' is CH<sub>2</sub> and q<sub>L</sub> is 0</p>	[0059]	

preferably





55. (withdrawn). Library as claimed in Claim 47 wherein each compound of formula I or I' comprises a moiety Lig and L as hereinbelow defined:

Wherein:

any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers

Lig<sub>2a</sub> is suitably of the formula, in either of the following forms given, including any of its possible linking configurations or sites:



[0060]

[0173]


[0061]

[0062]

<p>Lig<sup>1</sup><sub>m</sub></p>	<p>[0063] [0064] [0065]</p>	
<p>Wherein</p> <p>at least one or all of Ra<sup>1</sup> to Ra<sup>4</sup>, X<sup>1</sup> and X<sup>2</sup> comprise a linking site or functionality J as hereinbefore defined</p> <p>X<sup>1</sup> and X<sup>2</sup> are each independently selected from H, O, OR<sub>a</sub>, NR<sub>a</sub>, NHR<sub>a</sub>; X<sup>1</sup> and X<sup>2</sup> are each preferably O;</p> <p>each of Ra<sup>1</sup>, Ra<sup>2</sup>, Ra<sup>3</sup> and Ra<sup>4</sup> independently is selected from H or C<sub>1-4</sub> linear or branched alkyl optionally mono or multi hydroxy or halo substituted;</p>	<p>[0066]</p>	
<p>Ra<sup>4</sup> is selected from a heteroatom O, S or substituted or unsubstituted amine or saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo and cyano; including optionally substituted aryl, cycloalkyl, alkyl, ketone, (di)amine, (di)amide, alkoxy, cycloalkyl, carboxylic acid or optionally o-, m- or p- substituted phenyl wherein substituents include aryl,</p>	<p>[0067]</p>	

alkyl, cycloalkyl, heteroaryl or heteroalkyl, amine, amide, carboxyl, carbonyl or  $R_a^4$  comprises cyclohexyl, cyclopentyl, ethoxy,  $(CH_2)_2Ph$ ,  $CH_2Ph$ ,  $CONH(CH_2)_mCONH$ ,  $CH_2CONH(CH_2)_2NH$ ,  $CH_2PhNHCOCH_2$ ,  $CH_2CH_2OCOCH_2$ , succinimide ester,  $NHCOCH_2$ ,  $CH_2(CH_3)NCOCH_2$ ,  $H_2N(CH_2)_2NHCOCH_2$ ,  $H_2N(CH_2)_3NHCOCH_2$ ,  $H_2NNHCOCH_2$ ,  $CH_2CONH(CH_2)_2NHCOCH_2$ ,  $HOPhCH_2N(CH_2)_3HOAc$ ,  $(CH_2)_2NHCOCH_2$ , heterocyclic- $(CH_2)_4CONH(CH_2)_2NHCOCH_2$  or heterocyclic- $NHCON$ (heterocyclic) $COCH_2$ ;

or Lig a is of the formula Lig.a<sup>2</sup>-




wherein at least one or all of  $R_a^5$  to  $R_a^6$ , or a cyclic C or heteroatom comprise a linking site or functionality J as hereinbefore defined, each of  $C_{A1}$  and  $C_{A2}$  is independently selected from  $C_{5-6}$  aryl, heteroaryl, cycloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring  $-C=C-$  group;

Each of up to seven  $R_a^5$  is a substituent of a ring carbon or a ring heteroatom and:  
is independently selected from H, halo, hydroxy, thiol, amine,  $COOH$ , hydrazine, cyano, saturated or unsaturated, substituted or unsubstituted  $C_{1-20}$  branched or straight chain

<p>aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo =O or cyano; OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>3</sub>CON(CH<sub>3</sub>)c-hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, c-hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>;</p> <p>or any two or more of R.a<sup>5</sup> from a one, two or three ring fused cyclic structure, a fused 3 ring aryl, 5-heterocyclic or 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.a<sup>2</sup> structure;</p> <p>and R.a<sup>6</sup> is a moiety as defined for R.a<sup>5</sup> above;</p>	
<p>and L.a is as hereinbefore defined for L or J<sub>L</sub>, L<sub>J</sub> or L<sub>L</sub> or subformulae as hereinbefore defined, or is a single bond, amino acid or amide including a peptide or polypeptide gly or gly<sub>3</sub>, alkyl of formula -(CH<sub>2</sub>)<sub>n</sub> where n is 3 to 8, optionally including one or more heteroatoms or unsaturated groups, including -O- or -S- or -CH=CH-;</p>	
<p>Lig.b is suitably of the formula Lig.b including any of its possible linking configurations or sites:</p> <p>Lig.b</p>	

[0073]

[0072]



wherein  
at least one or all of Rb<sup>1</sup> to Rb<sup>5</sup> or Xb<sup>1</sup> to Xb<sup>3</sup> comprise a linking site or  
functionality J as hereinbefore defined [0074]

ring substituents X<sub>b</sub><sup>1</sup> and X<sub>b</sub><sup>2</sup> are independently selected from hydrocarbon including alkyl or  
SR<sub>x</sub>, NR<sub>x</sub><sub>2</sub> and OR<sub>x</sub> wherein (each) R<sub>x</sub> is selected from H, C<sub>1-8</sub>alkyl, alkenyl;  
ring heteroatom X<sub>b</sub><sup>3</sup> is selected from -S-, -O- and -CH<sub>2</sub>-; [0075]  
[0076]

Rb<sup>1</sup>  
is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-4</sub> aliphatic,  
or C<sub>1-3</sub> alicyclic optionally including one or more heteroatoms N, O, S, P, wherein  
substituent(s) are selected from one or more cycloalkyl, heterocyclic, hydroxy, oxo,  
halo, amine; or R<sub>b</sub><sup>1</sup> comprises a carbonyl substituted by H, alkyl or a linear or  
cyclic primary, secondary or tertiary amine, substituted C<sub>1-3</sub> alkyl, cycloalkyl or  
amide, cyclopropyl, or CONHC<sub>1-3</sub>alkyl including CONHt or CH<sub>2</sub>OH [0077]

and  
each of R<sub>b</sub><sup>2</sup> and R<sub>b</sub><sup>3</sup> is selected from H, halo, hydroxy, thiol, amine, COOH,  
CHO, hydrazine, cyano or saturated or unsaturated, substituted or unsubstituted C<sub>1-  
20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof,  
any of which may comprise one or more heteroatoms selected from N, O, S, P,  
wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or  
alicyclic substituents any of which may comprise one or more heteroatoms as [0078]

<p>hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano, preferably from H, halo or hydroxy;</p> <p>Rb<sup>4</sup> is H;</p> <p>Rb<sup>5</sup> is H or alkyl</p> <p>L.b comprises a linking site or functionality J as hereinbefore defined; and is as hereinbefore defined for L or its subformulae, more preferably is saturated and unsaturated substituted or unsubstituted C<sub>1-12</sub> aliphatic or C<sub>1-24</sub> aromatic as defined for L optionally including one or more heteroatoms O, S or N, cyclic or heterocyclic groups, or is of formula L.I or its subformulae as hereinbefore defined, or is (CH<sub>2</sub>)<sub>m</sub> wherein m is 2 to 12, or is (Ph-CH<sub>2</sub>CONH)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>;</p>	
<p>Lig c is of the formula Lig.c including any of its possible linking configurations or sites:</p> <p>Lig c      HOC*(R.c<sup>1</sup>)CH<sub>2</sub>NH-R.c<sup>2</sup></p> <div data-bbox="362 447 435 579"> </div> <p>where      at least one or all of R.c<sup>1</sup> to R.c<sup>2</sup> or OH, or a chain C or N comprise a linking site or functionality J as hereinbefore defined</p> <p>* indicates an optically active centre and</p> <p>wherein R.c<sup>1</sup> is C<sub>6-14</sub> aryl optionally including one or more heteroatoms selected from H, O,</p>	<p>[0079]</p> <p>[0080]</p> <p>[0081]</p> <p>[0082]</p> <p>[0083]</p> <p>[0084]</p> <p>[0085]</p>

optionally substituted by OH, Hal, NH<sub>2</sub>, NH(C<sub>1-3</sub>alkyl), sulphonamide, oxoamine or (-CONH<sub>2</sub>), or is mono, di or tri substituted phenyl or quinoline wherein substituents include OH, Cl or NH<sub>2</sub>, or is m-CH<sub>2</sub>OH, p-OH phenyl, m-,p-dihydroxy phenol or m-,m-dihydroxyphenol, m-,m-di-Cl, p-NH<sub>2</sub> phenol, p-OH, m-CONH<sub>2</sub> phenol or 5-OH, 8-quinoline,




R<sup>c2</sup> is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any optionally substituted C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amino, hydrazine, oxo or cyano and combinations thereof; or R<sup>c2</sup> is selected from C<sub>1-6</sub> branched or straight chain aliphatic, C<sub>6-10</sub> araliphatic optionally substituted by OH and optionally including heteroatoms selected from N,O, optionally including an ether O, and is selected from -(CH<sub>2</sub>)<sub>6</sub>OCH((CH<sub>2</sub>)<sub>3</sub>Ph), CHCH<sub>3</sub>(CH<sub>2</sub>)<sub>2</sub>Ph, CHCH<sub>3</sub>CH<sub>2</sub>PhOH,

[0086]

[0087]





C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>Ph or from the structures:



L.c is present as R.c<sup>2</sup> or comprises a linking site or functionality J as hereinbefore defined, and is as hereinbefore defined for L, formula L.1 or its subformulae as hereinbefore defined, or is selected from C<sub>1-12</sub> alkyl, amide;

[0088]

Lig.d is of the formula Lig.d including any of its possible linking configurations or sites:

Lig.d



where  
at least one or all of Rd<sup>1</sup> to Rd<sup>2</sup> or OH, a chain C or N comprise a linking site or functionality J as hereinbefore defined

[0089]



\* indicates an optically active centre

wherein  
R.d<sup>1</sup> is saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional



[0090]  
[0091]

substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano; or R, d<sup>1</sup> is substituted or unsubstituted C<sub>1-24</sub> aralkyl or heteroaralkyl, including single ring and fused ring systems with (hetero)aryl or cycloalkyl rings, wherein optional substituents include C<sub>1-6</sub> alkyl, alkoxy, ether, carbonyl, alkenyl, amine, amide each optionally carbonyl, amide, halo or OH substituted, or halo or OH, amine, amide, carbonyl, ketone, ether substituted phenyl or naphthyl, mono-, di-, tri- or tetra substituted mono or polycyclic fused aryl or cycloaryl or heterocycloaryl including phenyl, carbazole or structures shown below or spiro ring systems, mono-, di-, tri- or tetra alkoxyalkyl, alkoxyalkoxyalkyl or CF<sub>3</sub> substituted phenyl or unsubstituted or monosubstituted naphthalene or 5,6 ring systems:

[0092]





[0092]



R<sup>d3</sup>

is substituted or unsubstituted amine, saturated or unsaturated, substituted or unsubstituted C<sub>1-12</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo or cyano, more preferably amine, C<sub>1-6</sub> branched or straight chain alkyl optionally including ether O, and optionally substituted by C<sub>6-10</sub> aryl, or of the formula:

<p>L.d</p> <p>may be present as R,d<sup>2</sup> or may comprise a linking site or functionality J as hereinbefore defined and is as hereinbefore defined for L and its subformulae , formula L.1 and its subformulae as hereinbefore defined, or is a single bond or is as hereinbefore defined for L.a;</p> <p>Lige comprises a cell permeant moiety or is associated with a cell permeant L or FI moiety or is of the formula , in either of the following forms given including any of its possible linking configurations or sites:</p> <p>Lige<sup>1</sup></p> <div data-bbox="694 144 911 763"> </div>	<p>[0094]</p>
--	---------------



[0095]

[0096]


wherein at least one or all of  $Re^1$  to  $Re^4$ , X and a ring C or N comprise a linking site or functionality J as hereinbefore defined


h is selected from




[0097]

each optionally substituted by  $R.e^3 - R.e^4$  wherein  $R.e^1 - R.e^4$  are as  $R.a^1 - R.a^4$  defined above or in which  $R.e^3$  is  $C_{3-9}$  linear or branched alkyl, optionally mono or multi hydroxy or halo substituted or is aryl optionally substituted by alkoxy or

<p>sulfonyl,</p> <p>ortho-OEt, meta-SO<sub>2</sub>N</p>  <p>NCH<sub>3</sub></p>	[0098]	
<p>each X is independently selected from H, O, -OR<sup>e2</sup>, N, HN, NR<sup>e5</sup>, HR<sup>e6</sup>, and aryl optionally substituted by ether; or X is aryl optionally alkyl or alkoxy substituted or is Ph-ortho-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;</p>	[0099]	
<p>and</p> <p>where R<sup>e5</sup> is as defined above for R<sup>e1</sup> above or forms a fused cyclic ring together with the adjacent ring N atom, or 1 or 2 fused 5 membered cyclic rings;</p>	[0100]	
<p>and</p> <p>R<sup>e6</sup> is as defined above for R<sup>e1</sup> above or is selected from optionally substituted phenyl wherein optional substituents include ether, o-ethoxy or o-propoxy, alkyl or OH, sulphonyl or carbonyl substituted by heterocyclic, or cyclic C<sub>3-8</sub> alkyl, piperazinyl or sulphonyl;</p>		
<p>or Lig<sup>e</sup> is of the formula Lig<sup>e2</sup></p>		

<p><b>Lig<sup>e3</sup></b></p> <p>wherein</p> <p>at least one or all free ring atom or their substituents comprise a linking site or functionality J as hereinbefore defined</p> <p>each spiro ring optionally comprises zero or one or more heteroatoms h</p> <p>or</p> <p>  </p> <p>5,6(h) comprises zero, 1 or 2 N heteroatoms and is unsaturated or comprises one or two -C=C- or -C=N- groups; and wherein each ring is optionally substituted by one or more oxo, CO, COOH, C<sub>1-6</sub> alkyl or linear or cyclic alkoxy optionally substituted by one or more oxo, CO, COOH, CN, or C<sub>1-6</sub> alicyclic or amine groups, amine or one or more spiro or fused heterocycles;</p> <p>or Lig<sup>e</sup> is of the formula Lig<sup>e3</sup></p>	<p>[0101]</p> <p>[0102]</p> <p>[0103]</p> <p>[0104]</p>
---	---



wherein at least one or all of R.e<sup>11</sup> to R.e<sup>12</sup>, or a ring C or heteroatom or ring substituent comprise a linking site or functionality J as hereinbefore defined [0105]

each of C.e1 and C.e2 is independently selected from C<sub>5-6</sub> aryl, heteroaryl, cyloalkyl and heterocyclic, including phenyl, or aryl containing 1 or 2 ring heteroatoms, [0106]

or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group; each of up to seven R.e<sup>11</sup> is a substituent of a ring carbon or a ring heteroatom and: [0107]

is independently selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein [0108]

optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amino, hydrazine, oxo =O, or cyano, OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>,



<p>O(CH<sub>2</sub>)<sub>3</sub>CON(CH<sub>3</sub>)c<sub>6</sub>hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, c<sub>6</sub>hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>;  any two or more of R<sub>e</sub><sup>11</sup> form a one, two or three ring fused cyclic structure, a fused 3 ring aryl, 5-heterocyclic or 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig<sup>e3</sup> structure;  and R<sub>e</sub><sup>12</sup> is a moiety as defined for R<sub>e</sub><sup>11</sup> above;</p>	<p>[0109]</p>	
<p>L.e  comprises a linking site or functionality J as hereinbefore defined and is suitably as hereinbefore defined for L.a.</p>	<p>[0112]</p>	
<p>56. Canceled</p>		
<p>57 (withdrawn). Library as claimed in Claim 56 wherein FI is of formula Jr - t - FI and comprises a BODIPY™ structure characterised by a dipyrrometheneboron difluoride core, optionally modified by one or two fused rings, optionally substituted by one or several substituents selected from alkyl, alkoxy, aryl or heterocyclic, wherein one substituent -t- is adapted for linking as hereinbefore defined to a ligand precursor as hereinbefore defined, wherein the substituent -t- comprises a proximal unsaturated or aryl moiety, comprising a medial short, medium or long chain alkynyl or cycloalkyl moiety and comprising a moiety derived from linking via a reactive group as hereinbefore defined or selected from carboxyl, sulphonate or as a heteroatom O or S or methylene derived from linking at an alkylhalide including methylbromide, haloacetamide or sulphonate ester</p>	<p>[0118, line 8]    [0120, line 9-end]</p>	

electrophilic group.

58. Canceled		
59. (withdrawn and currently amended). Process for the preparation of a library as claimed in ef-Claim 47 which is a combinatorial process, and comprises the reaction of one or more ligand precursors of formula IV and/or IV'  IV      (LigL) <sub>m</sub> -L-Y <sub>Lm</sub>  IV'    Lig Y <sub>Lgm</sub>  comprising one or more or different reactive groups Y <sub>L</sub> or Y <sub>Lig</sub> forming a linking functionality J, J <sub>L</sub> or J <sub>r</sub> as hereinbefore defined  with one or more of a plurality of analytical tagging substrates of formula V and/or V'  V      Y <sub>rm</sub> Tag  V'    Y <sub>rm</sub> L (J <sub>r</sub> Tag) <sub>m</sub>  comprising one or more or different reactive groups Y <sub>r</sub> forming a linking functionality J or J <sub>r</sub> as hereinbefore defined  and optionally one or more linking species VI or VI' or VI''  VI    Y <sub>lm</sub> L Y <sub>lm</sub>  wherein Lig, J, L, J <sub>r</sub> and Tag and each m is independently as hereinbefore defined	[0132]	

<p>wherein the or each compound of formula IV or IV' is capable of reaction with the or each compound of formula V or V', optionally via the or each species VI or VI' or VI'' to form a plurality of compounds of formula I as hereinbefore defined;</p> <p>wherein linking is at same or different reactive sites in different compounds as hereinbefore defined.</p>		
<p>60 (withdrawn and currently amended). Process for the preparation of a compound of formula I as <del>hereinbefore</del> hereinbelow defined in Claim 47-64 comprising the reaction of a compound of formula IV or IV' and a compound of formula V or V' and optionally additionally V1, as hereinbefore defined in claim 59, <del>by reacting the unprotected primary-alkyl amine group of a compound of formula IV with a compound of formula V comprising a reactive succinimidy1 ester group in solvent at ambient temperature without the need for subsequent deprotection.</del></p>	[0142]	
<p>61-62 (canceled).</p> <p>63 (withdrawn and currently amended). <u>Method/Process</u> as claimed in Claim 62 59 which <u>comprises additionally determining pharmacology for a plurality of or all compounds in the library in order to enable selecting a compound exhibiting desired pharmacology, whereby the process comprises preparing a preliminary library of compounds, conducting screens to assess binding or</u></p>	[0154, line 6-81]	[0155]

inhibition, selecting a compound identified in the screen as having beneficial properties, and modifying or functionalising by nature of moieties or linking location of linking on the basis of the indications from the screen to prepare an optimised library, wherein the molecular pharmacology and photochemistry from the screen feedback into the design of the library.

<p>64. (currently amended). A compound of formula I</p> $(Lig)_m L (Tr Tag)_m (Tr L (L Lig)_m)_p$ <p>or salt thereof wherein an optically active ligand is present as a racemate or as one of its optically active isomers</p> <p>comprising ligand moiety Lig linked to tag moiety Tag via linker moiety L at linking site or linking functionality <math>L_T</math> and <math>L_L</math></p> <p>wherein Lig comprises a GPCR ligand, an inhibitor of an intracellular enzyme or a substrate or inhibitor of a drug transporter</p> <p>L is selected from a single or double bond, -O-, -S-, amine, COO-, amide, -NH-, hydrazine; and saturated or unsaturated, substituted or unsubstituted <math>C_{1-60}</math> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any <math>C_{1-20}</math> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore</p>	<p>[0159]</p> <p>[0173]</p>	
<p>[0114]</p>	<p>[0045]</p>	

defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano and carbonyl and combinations thereof, and L may be monomeric, oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300; are each independently selected from a whole number integer from 1 to 3;	[0015]	
p _____ is 0 to 3	[0017]	
wherein -Tag is a fluorophore entity -Fl, whereby the compound is of formula I'	[0018]	
$(\text{Lig})_m \text{L} (\text{Fl})_n (\text{L} (\text{Lig})_m)$	[0027]	
characterised in that Fl is selected from a red, near ir or blue dye with the proviso that:	[0115]	
a) when Lig is XAc ie in Lig, a when each of $\text{R}_a^1$ and $\text{R}_a^2$ is propyl, $\text{R}_a^3$ is H and $\text{R}_a^4$ is -Ph- $\text{OCH}_2\text{CONH}(\text{CH}_2)_2\text{NH}_2$ , and L is a single bond Fl is not BODIPY™ 630/650 X; or	[0170]	
b) when Lig is ABFA, ie m is 4 and L is a single bond Fl is not BODIPY™ 630/650 X; as hereinbefore defined in Claim 47 wherein $\text{H}_{\text{m}} \text{L} \text{F}_{\text{m}}$ is of formula	[0171]	
$\text{FAq}_1\text{R}_q\text{J}^{12}$		
wherein each of J and J <sup>12</sup> is amine or O, A is $\text{CH}_2\text{CH}_2\text{O}$ , $\text{q}_1$ is 1-30 or 31 to 300 and $\text{R}_q$ is $\text{CH}_2\text{CH}_3$		
or of formula		
$\text{J Aq}_1\text{R}_q(\text{A}^{12})\text{J}^{12}$		
wherein each of J, J <sup>12</sup> and J <sup>12</sup> independently is amine, O or a single bond, $\text{q}_1$ is 1, 2 or 3, 30 or 31 to 300 and A is $\text{CH}_2\text{CH}_2\text{O}$ or $\text{HNCH}_2\text{CO}$ or $\text{q}_1$ is 1 and A is C(O) or $(\text{CH}_2)_1$ , s or $\text{q}_1$ is 0, $\text{R}_q$ is CH or $\text{CH}_2\text{CH}_2$ , $\text{q}_1$ is 0 or $\text{q}_1^{12}$ is 1 and A <sup>12</sup> is $\text{CH}_2$ and $\text{q}_1^{12}$ is 0		

<p>preferably</p> $O(CH_2CH_2O)_q(CH_2CH_2NH_2O(CH_2CH_2O)_qCH_2CH(CH_2NH)NH_2$ $OCH(CH_2NH)NH_2-CH(CH_2NH)NH_2-C(O)NH_2-(CH_2)_{1-5}-\text{or}-(HNCH_2CO)_{1-3}(-gly_{1-3})$ <p>and wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers.</p>		
<p>65. (currently amended). A compound of formula I as defined in Claim 64 which is a compound of formula II or III as hereinafter defined in Claim 50</p> <p>II <math>(Lig)_m L - J_r Tag - J_r L (J_r Lig)_m</math> where each m is as hereinafter defined and is preferably 1 or 2, more preferably 1</p> <p>III <math>(Lig)_m L (J_r Tag)_m</math> wherein each m is as hereinafter defined and is preferably 1 and/or 2, more preferably</p> <p>Lig <math>J_L - L - J_L Tag</math> and/or</p> <p>Lig <math>J_L - L - J_r Tag</math> and/or</p> <p><math>J_L Lig</math> <math>J_r Tag</math></p> <p>as hereinafter defined in Claim 50 and wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers.</p>	<p>[0030]</p>	

<p>66. (currently amended). A compound according to Claim 64, wherein FI is of formula <math>J_r-t</math>—FI and comprises a BODIPY™ structure characterised by a dipyrrometheneboron difluoride core, optionally modified by one or two fused rings, optionally substituted by one or several substituents selected from alkyl, alkoxy, aryl or heterocyclic, wherein one substituent <math>-t</math> is adapted for linking as hereinbefore defined to a ligand precursor as hereinbefore defined, wherein the substituent <math>-t</math> comprises a proximal unsaturated or aryl moiety, comprising a medial short, medium or long chain alkynyl or cycloalkyl moiety and comprising a moiety derived from linking via a reactive group as hereinbefore defined or selected from carboxyl, sulphonate or as a heteroatom O or S or methylene derived from linking at an alkylhalide including methylbromide, haloacetamide or sulphonate ester electrophilic group. Lig comprises a GPCR ligand, an inhibitor of an intracellular enzyme or a substrate or inhibitor of a drug transporter or FI is a fluorophore entity, with the proviso that when Lig is CGP12177 and <math>t</math> is 1,1,4,4-tetramethyl butylamine <math>C(CH_3)_3C(CH_3)_2C(CH_3)_2NH_2</math>, FI is not BODIPY@FI, or when <math>t</math> is <math>C(CH_3)_3C(CH_3)_2C(CH_3)_2NHCSNH_2</math> then FI is not FITC, eosin or erythrosin</p> <p>characterised in that the or each FI is selected from a red, near ir or blue absorbing dye or from BODIPY@630/650 or BODIPY@630/650 X.</p>	<p>[0118]</p>	
<p>67. (currently amended). A compound of the formula I or I' as hereinbefore defined in Claim 56-55 selected from formulae Lig<sub>an</sub> L-a-FI<sub>a</sub>n to Lig<sub>en</sub> L-eFI<sub>e</sub>n as hereinbefore defined with the proviso that:</p>	<p>[0159]</p>	

<p>a) when Lig is XAG, ie in Lig-a when each of R.a<sup>1</sup> and R.a<sup>2</sup> is propyl, R.a<sup>3</sup> is H and R.a<sup>4</sup> is Ph-  OCH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, and L is a single bond or L is gly- and n-3 or L is NCS, Fl is not  fluorescein; or</p> <p>when Lig is XAG and L is a single bond or NCS, Fl is not fluorescein or NBD;</p> <p>b) when Lig is adenosine Fl is not Fmoc (CA 134:204756); or</p> <p>when Lig is ADAG, ie R.a<sup>1</sup> is CH<sub>2</sub>OH, R.b<sup>2</sup> and R.b<sup>3</sup> are H and L is (Ph-  CH<sub>2</sub>CONH)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub> or L is a single bond, Fl is not fluorescein, NBD or Rhodamine; or</p> <p>when Lig is NECA (incorporating the moiety (CH<sub>2</sub>)<sub>m</sub>) ie R.b<sup>2</sup> and R.b<sup>3</sup> are H and L is a  single bond, or is (CH<sub>2</sub>)<sub>m</sub> when m is 2,4,6,8 or 10 then Fl is not NBD, or when m is 3,4,6,8,10 or  12 then Fl is not dansyl; or</p> <p>when Lig is N<sup>6</sup>-(2-(4 aminophenyl)ethyl)adenosine and L is (CH<sub>2</sub>)<sub>2</sub>PhNH<sub>2</sub>, Fl is not FITC (CA  131:56155 (9))</p> <p>e) when Lig is GGP12177 and L (R.c<sup>4</sup>) is mono amine methane, Fl is not BODIPY@ TMR<sub>6</sub> or  when Lig is GGP12177 and L is 1,1,4,4 tetramethyl butylamine, ie  C(CH<sub>3</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>NH<sub>2</sub> Fl is not BODIPY@ Fl<sub>2</sub> or when L is  C(CH<sub>3</sub>)<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>NHCSNH<sub>2</sub> then Fl is not FITC, eosin or erythrosin; or when L is  monoamine methane, Fl is not FITC (CA 131:56155 (4)); or</p> <p>when Lig is GGP12177 and L is a single bond, Fl is not NBD<sub>2</sub> or</p> <p>when Lig is alprenolol ie o-prop-2-nyl phenyl and L is C(CH<sub>3</sub>)<sub>2</sub> or a single bond, Fl is not  NBD<sub>2</sub></p> <p>and e)-e) when L is a single bond, Fl is not BODIPY Fl<sub>2</sub></p>		
---	--	--



<p>optionally additionally</p> <p>a) when Lig is XAC ie in Lig a when each of R.a<sup>1</sup> and R.a<sup>2</sup> is propyl, R.a<sup>3</sup> is H and R.a<sup>4</sup> is -Ph-OCH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, and L is a single bond FI is not BODIPY™ 630/650 X; or</p> <p>b) when Lig is ABEA, ie m is 4 and L is a single bond FI is not BODIPY™ 630/650 X.</p>	<p>[0170]</p> <p>[0171]</p>	
<p>68. (currently amended). A compound of the formula I</p> $\text{(Lig L)}_m\text{L}(\text{L}_T\text{Tag})_n(\text{L}_L\text{Lig})_p$ <p>or salt thereof and salts thereof wherein an optically active ligand is present as a racemate or as one of its optically active isomers</p> <p>comprising ligand moiety Lig linked to tag moiety Tag via linker moiety L at linking site or linking functionality L<sub>T</sub> and L<sub>L</sub></p> <p>wherein Lig comprises a GPCR ligand, an inhibitor of an intracellular enzyme or a substrate or inhibitor of a drug transporter:</p> <p>L is selected from a single or double bond -O-, -S-, amine, COO-, amide, -NN-, hydrazine, and saturated or unsaturated, substituted or unsubstituted C<sub>1-600</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein</p>	<p>[0159]</p> <p>[0173]</p> <p>[0114]</p> <p>[0045]</p>	

<p>optional substituents are selected from any C<sub>1-20</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano and carbonyl and combinations thereof, and L may be monomeric, oligomeric having olefinic repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300;</p> <p>m are each independently selected from a whole number integer from 1 to 3;</p> <p>n is 0 to 3</p>	
<p>wherein -Tag is a fluorophore entity -Fl, whereby the compound is of formula I'</p> <p>(Ia)<sub>1</sub>, (Ib)<sub>2</sub>, (Ic)<sub>3</sub>, (Id)<sub>4</sub>, (Ie)<sub>5</sub>, (If)<sub>6</sub>, (Ig)<sub>7</sub>, (Ih)<sub>8</sub>, (Ii)<sub>9</sub>, (Ij)<sub>10</sub>, (Ik)<sub>11</sub>, (Il)<sub>12</sub>, (Im)<sub>13</sub>, (In)<sub>14</sub>, (Io)<sub>15</sub>, (Ip)<sub>16</sub>, (Iq)<sub>17</sub>, (Ir)<sub>18</sub>, (Is)<sub>19</sub>, (It)<sub>20</sub>, (Iu)<sub>21</sub>, (Iv)<sub>22</sub>, (Iw)<sub>23</sub>, (Ix)<sub>24</sub>, (Iy)<sub>25</sub>, (Iz)<sub>26</sub>, (Iaa)<sub>27</sub>, (Iab)<sub>28</sub>, (Iac)<sub>29</sub>, (Iad)<sub>30</sub>, (Iae)<sub>31</sub>, (Iaf)<sub>32</sub>, (Iag)<sub>33</sub>, (Iah)<sub>34</sub>, (Iai)<sub>35</sub>, (Iaj)<sub>36</sub>, (Iak)<sub>37</sub>, (Ial)<sub>38</sub>, (Iam)<sub>39</sub>, (Ian)<sub>40</sub>, (Iao)<sub>41</sub>, (Iap)<sub>42</sub>, (Iaq)<sub>43</sub>, (Iar)<sub>44</sub>, (Ias)<sub>45</sub>, (Iat)<sub>46</sub>, (Iau)<sub>47</sub>, (Iav)<sub>48</sub>, (Iaw)<sub>49</sub>, (Iax)<sub>50</sub>, (Iay)<sub>51</sub>, (Iaz)<sub>52</sub>, (Iba)<sub>53</sub>, (Ibb)<sub>54</sub>, (Ibc)<sub>55</sub>, (Ibd)<sub>56</sub>, (Ibe)<sub>57</sub>, (Ibf)<sub>58</sub>, (Ibg)<sub>59</sub>, (Ibh)<sub>60</sub>, (Ibi)<sub>61</sub>, (Ibj)<sub>62</sub>, (Ibk)<sub>63</sub>, (Ibl)<sub>64</sub>, (Ibm)<sub>65</sub>, (Ibn)<sub>66</sub>, (Ibo)<sub>67</sub>, (Ibp)<sub>68</sub>, (Ibq)<sub>69</sub>, (Ibr)<sub>70</sub>, (Ibs)<sub>71</sub>, (Ibt)<sub>72</sub>, (Ibu)<sub>73</sub>, (Ibv)<sub>74</sub>, (Ibw)<sub>75</sub>, (Ibx)<sub>76</sub>, (Iby)<sub>77</sub>, (Ibz)<sub>78</sub>, (Ica)<sub>79</sub>, (Icb)<sub>80</sub>, (Icc)<sub>81</sub>, (Icd)<sub>82</sub>, (Ice)<sub>83</sub>, (Icf)<sub>84</sub>, (Icg)<sub>85</sub>, (Ich)<sub>86</sub>, (Ici)<sub>87</sub>, (Icj)<sub>88</sub>, (Ick)<sub>89</sub>, (Icl)<sub>90</sub>, (Icm)<sub>91</sub>, (Icn)<sub>92</sub>, (Ico)<sub>93</sub>, (Icp)<sub>94</sub>, (Icq)<sub>95</sub>, (Icr)<sub>96</sub>, (Ics)<sub>97</sub>, (Ict)<sub>98</sub>, (Icu)<sub>99</sub>, (Icv)<sub>100</sub>, (Icw)<sub>101</sub>, (Icx)<sub>102</sub>, (Icy)<sub>103</sub>, (Icz)<sub>104</sub>, (Ica)<sub>105</sub>, (Icb)<sub>106</sub>, (Icc)<sub>107</sub>, (Icd)<sub>108</sub>, (Ice)<sub>109</sub>, (Icf)<sub>110</sub>, (Icg)<sub>111</sub>, (Ich)<sub>112</sub>, (Ici)<sub>113</sub>, (Icj)<sub>114</sub>, (Ick)<sub>115</sub>, (Icl)<sub>116</sub>, (Icm)<sub>117</sub>, (Icn)<sub>118</sub>, (Ico)<sub>119</sub>, (Icp)<sub>120</sub>, (Icq)<sub>121</sub>, (Icr)<sub>122</sub>, (Ics)<sub>123</sub>, (Ict)<sub>124</sub>, (Icu)<sub>125</sub>, (Icv)<sub>126</sub>, (Icw)<sub>127</sub>, (Icx)<sub>128</sub>, (Icy)<sub>129</sub>, (Icz)<sub>130</sub>, (Ica)<sub>131</sub>, (Icb)<sub>132</sub>, (Icc)<sub>133</sub>, (Icd)<sub>134</sub>, (Ice)<sub>135</sub>, (Icf)<sub>136</sub>, (Icg)<sub>137</sub>, (Ich)<sub>138</sub>, (Ici)<sub>139</sub>, (Icj)<sub>140</sub>, (Ick)<sub>141</sub>, (Icl)<sub>142</sub>, (Icm)<sub>143</sub>, (Icn)<sub>144</sub>, (Ico)<sub>145</sub>, (Icp)<sub>146</sub>, (Icq)<sub>147</sub>, (Icr)<sub>148</sub>, (Ics)<sub>149</sub>, (Ict)<sub>150</sub>, (Icu)<sub>151</sub>, (Icv)<sub>152</sub>, (Icw)<sub>153</sub>, (Icx)<sub>154</sub>, (Icy)<sub>155</sub>, (Icz)<sub>156</sub>, (Ica)<sub>157</sub>, (Icb)<sub>158</sub>, (Icc)<sub>159</sub>, (Icd)<sub>160</sub>, (Ice)<sub>161</sub>, (Icf)<sub>162</sub>, (Icg)<sub>163</sub>, (Ich)<sub>164</sub>, (Ici)<sub>165</sub>, (Icj)<sub>166</sub>, (Ick)<sub>167</sub>, (Icl)<sub>168</sub>, (Icm)<sub>169</sub>, (Icn)<sub>170</sub>, (Ico)<sub>171</sub>, (Icp)<sub>172</sub>, (Icq)<sub>173</sub>, (Icr)<sub>174</sub>, (Ics)<sub>175</sub>, (Ict)<sub>176</sub>, (Icu)<sub>177</sub>, (Icv)<sub>178</sub>, (Icw)<sub>179</sub>, (Icx)<sub>180</sub>, (Icy)<sub>181</sub>, (Icz)<sub>182</sub>, (Ica)<sub>183</sub>, (Icb)<sub>184</sub>, (Icc)<sub>185</sub>, (Icd)<sub>186</sub>, (Ice)<sub>187</sub>, (Icf)<sub>188</sub>, (Icg)<sub>189</sub>, (Ich)<sub>190</sub>, (Ici)<sub>191</sub>, (Icj)<sub>192</sub>, (Ick)<sub>193</sub>, (Icl)<sub>194</sub>, (Icm)<sub>195</sub>, (Icn)<sub>196</sub>, (Ico)<sub>197</sub>, (Icp)<sub>198</sub>, (Icq)<sub>199</sub>, (Icr)<sub>200</sub>, (Ics)<sub>201</sub>, (Ict)<sub>202</sub>, (Icu)<sub>203</sub>, (Icv)<sub>204</sub>, (Icw)<sub>205</sub>, (Icx)<sub>206</sub>, (Icy)<sub>207</sub>, (Icz)<sub>208</sub>, (Ica)<sub>209</sub>, (Icb)<sub>210</sub>, (Icc)<sub>211</sub>, (Icd)<sub>212</sub>, (Ice)<sub>213</sub>, (Icf)<sub>214</sub>, (Icg)<sub>215</sub>, (Ich)<sub>216</sub>, (Ici)<sub>217</sub>, (Icj)<sub>218</sub>, (Ick)<sub>219</sub>, (Icl)<sub>220</sub>, (Icm)<sub>221</sub>, (Icn)<sub>222</sub>, (Ico)<sub>223</sub>, (Icp)<sub>224</sub>, (Icq)<sub>225</sub>, (Icr)<sub>226</sub>, (Ics)<sub>227</sub>, (Ict)<sub>228</sub>, (Icu)<sub>229</sub>, (Icv)<sub>230</sub>, (Icw)<sub>231</sub>, (Icx)<sub>232</sub>, (Icy)<sub>233</sub>, (Icz)<sub>234</sub>, (Ica)<sub>235</sub>, (Icb)<sub>236</sub>, (Icc)<sub>237</sub>, (Icd)<sub>238</sub>, (Ice)<sub>239</sub>, (Icf)<sub>240</sub>, (Icg)<sub>241</sub>, (Ich)<sub>242</sub>, (Ici)<sub>243</sub>, (Icj)<sub>244</sub>, (Ick)<sub>245</sub>, (Icl)<sub>246</sub>, (Icm)<sub>247</sub>, (Icn)<sub>248</sub>, (Ico)<sub>249</sub>, (Icp)<sub>250</sub>, (Icq)<sub>251</sub>, (Icr)<sub>252</sub>, (Ics)<sub>253</sub>, (Ict)<sub>254</sub>, (Icu)<sub>255</sub>, (Icv)<sub>256</sub>, (Icw)<sub>257</sub>, (Icx)<sub>258</sub>, (Icy)<sub>259</sub>, (Icz)<sub>260</sub>, (Ica)<sub>261</sub>, (Icb)<sub>262</sub>, (Icc)<sub>263</sub>, (Icd)<sub>264</sub>, (Ice)<sub>265</sub>, (Icf)<sub>266</sub>, (Icg)<sub>267</sub>, (Ich)<sub>268</sub>, (Ici)<sub>269</sub>, (Icj)<sub>270</sub>, (Ick)<sub>271</sub>, (Icl)<sub>272</sub>, (Icm)<sub>273</sub>, (Icn)<sub>274</sub>, (Ico)<sub>275</sub>, (Icp)<sub>276</sub>, (Icq)<sub>277</sub>, (Icr)<sub>278</sub>, (Ics)<sub>279</sub>, (Ict)<sub>280</sub>, (Icu)<sub>281</sub>, (Icv)<sub>282</sub>, (Icw)<sub>283</sub>, (Icx)<sub>284</sub>, (Icy)<sub>285</sub>, (Icz)<sub>286</sub>, (Ica)<sub>287</sub>, (Icb)<sub>288</sub>, (Icc)<sub>289</sub>, (Icd)<sub>290</sub>, (Ice)<sub>291</sub>, (Icf)<sub>292</sub>, (Icg)<sub>293</sub>, (Ich)<sub>294</sub>, (Ici)<sub>295</sub>, (Icj)<sub>296</sub>, (Ick)<sub>297</sub>, (Icl)<sub>298</sub>, (Icm)<sub>299</sub>, (Icn)<sub>300</sub>, (Ico)<sub>301</sub>, (Icp)<sub>302</sub>, (Icq)<sub>303</sub>, (Icr)<sub>304</sub>, (Ics)<sub>305</sub>, (Ict)<sub>306</sub>, (Icu)<sub>307</sub>, (Icv)<sub>308</sub>, (Icw)<sub>309</sub>, (Icx)<sub>310</sub>, (Icy)<sub>311</sub>, (Icz)<sub>312</sub>, (Ica)<sub>313</sub>, (Icb)<sub>314</sub>, (Icc)<sub>315</sub>, (Icd)<sub>316</sub>, (Ice)<sub>317</sub>, (Icf)<sub>318</sub>, (Icg)<sub>319</sub>, (Ich)<sub>320</sub>, (Ici)<sub>321</sub>, (Icj)<sub>322</sub>, (Ick)<sub>323</sub>, (Icl)<sub>324</sub>, (Icm)<sub>325</sub>, (Icn)<sub>326</sub>, (Ico)<sub>327</sub>, (Icp)<sub>328</sub>, (Icq)<sub>329</sub>, (Icr)<sub>330</sub>, (Ics)<sub>331</sub>, (Ict)<sub>332</sub>, (Icu)<sub>333</sub>, (Icv)<sub>334</sub>, (Icw)<sub>335</sub>, (Icx)<sub>336</sub>, (Icy)<sub>337</sub>, (Icz)<sub>338</sub>, (Ica)<sub>339</sub>, (Icb)<sub>340</sub>, (Icc)<sub>341</sub>, (Icd)<sub>342</sub>, (Ice)<sub>343</sub>, (Icf)<sub>344</sub>, (Icg)<sub>345</sub>, (Ich)<sub>346</sub>, (Ici)<sub>347</sub>, (Icj)<sub>348</sub>, (Ick)<sub>349</sub>, (Icl)<sub>350</sub>, (Icm)<sub>351</sub>, (Icn)<sub>352</sub>, (Ico)<sub>353</sub>, (Icp)<sub>354</sub>, (Icq)<sub>355</sub>, (Icr)<sub>356</sub>, (Ics)<sub>357</sub>, (Ict)<sub>358</sub>, (Icu)<sub>359</sub>, (Icv)<sub>360</sub>, (Icw)<sub>361</sub>, (Icx)<sub>362</sub>, (Icy)<sub>363</sub>, (Icz)<sub>364</sub>, (Ica)<sub>365</sub>, (Icb)<sub>366</sub>, (Icc)<sub>367</sub>, (Icd)<sub>368</sub>, (Ice)<sub>369</sub>, (Icf)<sub>370</sub>, (Icg)<sub>371</sub>, (Ich)<sub>372</sub>, (Ici)<sub>373</sub>, (Icj)<sub>374</sub>, (Ick)<sub>375</sub>, (Icl)<sub>376</sub>, (Icm)<sub>377</sub>, (Icn)<sub>378</sub>, (Ico)<sub>379</sub>, (Icp)<sub>380</sub>, (Icq)<sub>381</sub>, (Icr)<sub>382</sub>, (Ics)<sub>383</sub>, (Ict)<sub>384</sub>, (Icu)<sub>385</sub>, (Icv)<sub>386</sub>, (Icw)<sub>387</sub>, (Icx)<sub>388</sub>, (Icy)<sub>389</sub>, (Icz)<sub>390</sub>, (Ica)<sub>391</sub>, (Icb)<sub>392</sub>, (Icc)<sub>393</sub>, (Icd)<sub>394</sub>, (Ice)<sub>395</sub>, (Icf)<sub>396</sub>, (Icg)<sub>397</sub>, (Ich)<sub>398</sub>, (Ici)<sub>399</sub>, (Icj)<sub>400</sub>, (Ick)<sub>401</sub>, (Icl)<sub>402</sub>, (Icm)<sub>403</sub>, (Icn)<sub>404</sub>, (Ico)<sub>405</sub>, (Icp)<sub>406</sub>, (Icq)<sub>407</sub>, (Icr)<sub>408</sub>, (Ics)<sub>409</sub>, (Ict)<sub>410</sub>, (Icu)<sub>411</sub>, (Icv)<sub>412</sub>, (Icw)<sub>413</sub>, (Icx)<sub>414</sub>, (Icy)<sub>415</sub>, (Icz)<sub>416</sub>, (Ica)<sub>417</sub>, (Icb)<sub>418</sub>, (Icc)<sub>419</sub>, (Icd)<sub>420</sub>, (Ice)<sub>421</sub>, (Icf)<sub>422</sub>, (Icg)<sub>423</sub>, (Ich)<sub>424</sub>, (Ici)<sub>425</sub>, (Icj)<sub>426</sub>, (Ick)<sub>427</sub>, (Icl)<sub>428</sub>, (Icm)<sub>429</sub>, (Icn)<sub>430</sub>, (Ico)<sub>431</sub>, (Icp)<sub>432</sub>, (Icq)<sub>433</sub>, (Icr)<sub>434</sub>, (Ics)<sub>435</sub>, (Ict)<sub>436</sub>, (Icu)<sub>437</sub>, (Icv)<sub>438</sub>, (Icw)<sub>439</sub>, (Icx)<sub>440</sub>, (Icy)<sub>441</sub>, (Icz)<sub>442</sub>, (Ica)<sub>443</sub>, (Icb)<sub>444</sub>, (Icc)<sub>445</sub>, (Icd)<sub>446</sub>, (Ice)<sub>447</sub>, (Icf)<sub>448</sub>, (Icg)<sub>449</sub>, (Ich)<sub>450</sub>, (Ici)<sub>451</sub>, (Icj)<sub>452</sub>, (Ick)<sub>453</sub>, (Icl)<sub>454</sub>, (Icm)<sub>455</sub>, (Icn)<sub>456</sub>, (Ico)<sub>457</sub>, (Icp)<sub>458</sub>, (Icq)<sub>459</sub>, (Icr)<sub>460</sub>, (Ics)<sub>461</sub>, (Ict)<sub>462</sub>, (Icu)<sub>463</sub>, (Icv)<sub>464</sub>, (Icw)<sub>465</sub>, (Icx)<sub>466</sub>, (Icy)<sub>467</sub>, (Icz)<sub>468</sub>, (Ica)<sub>469</sub>, (Icb)<sub>470</sub>, (Icc)<sub>471</sub>, (Icd)<sub>472</sub>, (Ice)<sub>473</sub>, (Icf)<sub>474</sub>, (Icg)<sub>475</sub>, (Ich)<sub>476</sub>, (Ici)<sub>477</sub>, (Icj)<sub>478</sub>, (Ick)<sub>479</sub>, (Icl)<sub>480</sub>, (Icm)<sub>481</sub>, (Icn)<sub>482</sub>, (Ico)<sub>483</sub>, (Icp)<sub>484</sub>, (Icq)<sub>485</sub>, (Icr)<sub>486</sub>, (Ics)<sub>487</sub>, (Ict)<sub>488</sub>, (Icu)<sub>489</sub>, (Icv)<sub>490</sub>, (Icw)<sub>491</sub>, (Icx)<sub>492</sub>, (Icy)<sub>493</sub>, (Icz)<sub>494</sub>, (Ica)<sub>495</sub>, (Icb)<sub>496</sub>, (Icc)<sub>497</sub>, (Icd)<sub>498</sub>, (Ice)<sub>499</sub>, (Icf)<sub>500</sub>, (Icg)<sub>501</sub>, (Ich)<sub>502</sub>, (Ici)<sub>503</sub>, (Icj)<sub>504</sub>, (Ick)<sub>505</sub>, (Icl)<sub>506</sub>, (Icm)<sub>507</sub>, (Icn)<sub>508</sub>, (Ico)<sub>509</sub>, (Icp)<sub>510</sub>, (Icq)<sub>511</sub>, (Icr)<sub>512</sub>, (Ics)<sub>513</sub>, (Ict)<sub>514</sub>, (Icu)<sub>515</sub>, (Icv)<sub>516</sub>, (Icw)<sub>517</sub>, (Icx)<sub>518</sub>, (Icy)<sub>519</sub>, (Icz)<sub>520</sub>, (Ica)<sub>521</sub>, (Icb)<sub>522</sub>, (Icc)<sub>523</sub>, (Icd)<sub>524</sub>, (Ice)<sub>525</sub>, (Icf)<sub>526</sub>, (Icg)<sub>527</sub>, (Ich)<sub>528</sub>, (Ici)<sub>529</sub>, (Icj)<sub>530</sub>, (Ick)<sub>531</sub>, (Icl)<sub>532</sub>, (Icm)<sub>533</sub>, (Icn)<sub>534</sub>, (Ico)<sub>535</sub>, (Icp)<sub>536</sub>, (Icq)<sub>537</sub>, (Icr)<sub>538</sub>, (Ics)<sub>539</sub>, (Ict)<sub>540</sub>, (Icu)<sub>541</sub>, (Icv)<sub>542</sub>, (Icw)<sub>543</sub>, (Icx)<sub>544</sub>, (Icy)<sub>545</sub>, (Icz)<sub>546</sub>, (Ica)<sub>547</sub>, (Icb)<sub>548</sub>, (Icc)<sub>549</sub>, (Icd)<sub>550</sub>, (Ice)<sub>551</sub>, (Icf)<sub>552</sub>, (Icg)<sub>553</sub>, (Ich)<sub>554</sub>, (Ici)<sub>555</sub>, (Icj)<sub>556</sub>, (Ick)<sub>557</sub>, (Icl)<sub>558</sub>, (Icm)<sub>559</sub>, (Icn)<sub>560</sub>, (Ico)<sub>561</sub>, (Icp)<sub>562</sub>, (Icq)<sub>563</sub>, (Icr)<sub>564</sub>, (Ics)<sub>565</sub>, (Ict)<sub>566</sub>, (Icu)<sub>567</sub>, (Icv)<sub>568</sub>, (Icw)<sub>569</sub>, (Icx)<sub>570</sub>, (Icy)<sub>571</sub>, (Icz)<sub>572</sub>, (Ica)<sub>573</sub>, (Icb)<sub>574</sub>, (Icc)<sub>575</sub>, (Icd)<sub>576</sub>, (Ice)<sub>577</sub>, (Icf)<sub>578</sub>, (Icg)<sub>579</sub>, (Ich)<sub>580</sub>, (Ici)<sub>581</sub>, (Icj)<sub>582</sub>, (Ick)<sub>583</sub>, (Icl)<sub>584</sub>, (Icm)<sub>585</sub>, (Icn)<sub>586</sub>, (Ico)<sub>587</sub>, (Icp)<sub>588</sub>, (Icq)<sub>589</sub>, (Icr)<sub>590</sub>, (Ics)<sub>591</sub>, (Ict)<sub>592</sub>, (Icu)<sub>593</sub>, (Icv)<sub>594</sub>, (Icw)<sub>595</sub>, (Icx)<sub>596</sub>, (Icy)<sub>597</sub>, (Icz)<sub>598</sub>, (Ica)<sub>599</sub>, (Icb)<sub>600</sub>, (Icc)<sub>601</sub>, (Icd)<sub>602</sub>, (Ice)<sub>603</sub>, (Icf)<sub>604</sub>, (Icg)<sub>605</sub>, (Ich)<sub>606</sub>, (Ici)<sub>607</sub>, (Icj)<sub>608</sub>, (Ick)<sub>609</sub>, (Icl)<sub>610</sub>, (Icm)<sub>611</sub>, (Icn)<sub>612</sub>, (Ico)<sub>613</sub>, (Icp)<sub>614</sub>, (Icq)<sub>615</sub>, (Icr)<sub>616</sub>, (Ics)<sub>617</sub>, (Ict)<sub>618</sub>, (Icu)<sub>619</sub>, (Icv)<sub>620</sub>, (Icw)<sub>621</sub>, (Icx)<sub>622</sub>, (Icy)<sub>623</sub>, (Icz)<sub>624</sub>, (Ica)<sub>625</sub>, (Icb)<sub>626</sub>, (Icc)<sub>627</sub>, (Icd)<sub>628</sub>, (Ice)<sub>629</sub>, (Icf)<sub>630</sub>, (Icg)<sub>631</sub>, (Ich)<sub>632</sub>, (Ici)<sub>633</sub>, (Icj)<sub>634</sub>, (Ick)<sub>635</sub>, (Icl)<sub>636</sub>, (Icm)<sub>637</sub>, (Icn)<sub>638</sub>, (Ico)<sub>639</sub>, (Icp)<sub>640</sub>, (Icq)<sub>641</sub>, (Icr)<sub>642</sub>, (Ics)<sub>643</sub>, (Ict)<sub>644</sub>, (Icu)<sub>645</sub>, (Icv)<sub>646</sub>, (Icw)<sub>647</sub>, (Icx)<sub>648</sub>, (Icy)<sub>649</sub>, (Icz)<sub>650</sub>, (Ica)<sub>651</sub>, (Icb)<sub>652</sub>, (Icc)<sub>653</sub>, (Icd)<sub>654</sub>, (Ice)<sub>655</sub>, (Icf)<sub>656</sub>, (Icg)<sub>657</sub>, (Ich)<sub>658</sub>, (Ici)<sub>659</sub>, (Icj)<sub>660</sub>, (Ick)<sub>661</sub>, (Icl)<sub>662</sub>, (Icm)<sub>663</sub>, (Icn)<sub>664</sub>, (Ico)<sub>665</sub>, (Icp)<sub>666</sub>, (Icq)<sub>667</sub>, (Icr)<sub>668</sub>, (Ics)<sub>669</sub>, (Ict)<sub>670</sub>, (Icu)<sub>671</sub>, (Icv)<sub>672</sub>, (Icw)<sub>673</sub>, (Icx)<sub>674</sub>, (Icy)<sub>675</sub>, (Icz)<sub>676</sub>, (Ica)<sub>677</sub>, (Icb)<sub>678</sub>, (Icc)<sub>679</sub>, (Icd)<sub>680</sub>, (Ice)<sub>681</sub>, (Icf)<sub>682</sub>, (Icg)<sub>683</sub>, (Ich)<sub>684</sub>, (Ici)<sub>685</sub>, (Icj)<sub>686</sub>, (Ick)<sub>687</sub>, (Icl)<sub>688</sub>, (Icm)<sub>689</sub>, (Icn)<sub>690</sub>, (Ico)<sub>691</sub>, (Icp)<sub>692</sub>, (Icq)<sub>693</sub>, (Icr)<sub>694</sub>, (Ics)<sub>695</sub>, (Ict)<sub>696</sub>, (Icu)<sub>697</sub>, (Icv)<sub>698</sub>, (Icw)<sub>699</sub>, (Icx)<sub>700</sub>, (Icy)<sub>701</sub>, (Icz)<sub>702</sub>, (Ica)<sub>703</sub>, (Icb)<sub>704</sub>, (Icc)<sub>705</sub>, (Icd)<sub>706</sub>, (Ice)<sub>707</sub>, (Icf)<sub>708</sub>, (Icg)<sub>709</sub>, (Ich)<sub>710</sub>, (Ici)<sub>711</sub>, (Icj)<sub>712</sub>, (Ick)<sub>713</sub>, (Icl)<sub>714</sub>, (Icm)<sub>715</sub>, (Icn)<sub>716</sub>, (Ico)<sub>717</sub>, (Icp)<sub>718</sub>, (Icq)<sub>719</sub>, (Icr)<sub>720</sub>, (Ics)<sub>721</sub>, (Ict)<sub>722</sub>, (Icu)<sub>723</sub>, (Icv)<sub>724</sub>, (Icw)<sub>725</sub>, (Icx)<sub>726</sub>, (Icy)<sub>727</sub>, (Icz)<sub>728</sub>, (Ica)<sub>729</sub>, (Icb)<sub>730</sub>, (Icc)<sub>731</sub>, (Icd)<sub>732</sub>, (Ice)<sub>733</sub>, (Icf)<sub>734</sub>, (Icg)<sub>735</sub>, (Ich)<sub>736</sub>, (Ici)<sub>737</sub>, (Icj)<sub>738</sub>, (Ick)<sub>739</sub>, (Icl)<sub>740</sub>, (Icm)<sub>741</sub>, (Icn)<sub>742</sub>, (Ico)<sub>743</sub>, (Icp)<sub>744</sub>, (Icq)<sub>745</sub>, (Icr)<sub>746</sub>, (Ics)<sub>747</sub>, (Ict)<sub>748</sub>, (Icu)<sub>749</sub>, (Icv)<sub>750</sub>, (Icw)<sub>751</sub>, (Icx)<sub>752</sub>, (Icy)<sub>753</sub>, (Icz)<sub>754</sub>, (Ica)<sub>755</sub>, (Icb)<sub>756</sub>, (Icc)<sub>757</sub>, (Icd)<sub>758</sub>, (Ice)<sub>759</sub>, (Icf)<sub>760</sub>, (Icg)<sub>761</sub>, (Ich)<sub>762</sub>, (Ici)<sub>763</sub>, (Icj)<sub>764</sub>, (Ick)<sub>765</sub>, (Icl)<sub>766</sub>, (Icm)<sub>767</sub>, (Icn)<sub>768</sub>, (Ico)<sub>769</sub>, (Icp)<sub>770</sub>, (Icq)<sub>771</sub>, (Icr)<sub>772</sub>, (Ics)<sub>773</sub>, (Ict)<sub>774</sub>, (Icu)<sub>775</sub>, (Icv)<sub>776</sub>, (Icw)<sub>777</sub>, (Icx)<sub>778</sub>, (Icy)<sub>779</sub>, (Icz)<sub>780</sub>, (Ica)<sub>781</sub>, (Icb)<sub>782</sub>, (Icc)<sub>783</sub>, (Icd)<sub>784</sub>, (Ice)<sub>785</sub>, (Icf)<sub>786</sub>, (Icg)<sub>787</sub>, (Ich)<sub>788</sub>, (Ici)<sub>789</sub>, (Icj)<sub>790</sub>, (Ick)<sub>791</sub>, (Icl)<sub>792</sub>, (Icm)<sub>793</sub>, (Icn)<sub>794</sub>, (Ico)<sub>795</sub>, (Icp)<sub>796</sub>, (Icq)<sub>797</sub>, (Icr)<sub>798</sub>, (Ics)<sub>799</sub>, (Ict)<sub>800</sub>, (Icu)<sub>801</sub>, (Icv)<sub>802</sub>, (Icw)<sub>803</sub>, (Icx)<sub>804</sub>, (Icy)<sub>805</sub>, (Icz)<sub>806</sub>, (Ica)<sub>807</sub>, (Icb)<sub>808</sub>, (Icc)<sub>809</sub>, (Icd)<sub>810</sub>, (Ice)<sub>811</sub>, (Icf)<sub>812</sub>, (Icg)<sub>813</sub>, (Ich)<sub>814</sub>, (Ici)<sub>815</sub>, (Icj)<sub>816</sub>, (Ick)<sub>817</sub>, (Icl)<sub>818</sub>, (Icm)<sub>819</sub>, (Icn)<sub>820</sub>, (Ico)<sub>821</sub>, (Icp)<sub>822</sub>, (Icq)<sub>823</sub>, (Icr)<sub>824</sub>, (Ics)<sub>825</sub>, (Ict)<sub>826</sub>, (Icu)<sub>827</sub>, (Icv)<sub>828</sub>, (Icw)<sub>829</sub>, (Icx)<sub>830</sub>, (Icy)<sub>831</sub>, (Icz)<sub>832</sub>, (Ica)<sub>833</sub>, (Icb)<sub>834</sub>, (Icc)<sub>835</sub>, (Icd)<sub>836</sub>, (Ice)<sub>837</sub>, (Icf)<sub>838</sub>, (Icg)<sub>839</sub>, (Ich)<sub>840</sub>, (Ici)<sub>841</sub>, (Icj)<sub>842</sub>, (Ick)<sub>843</sub>, (Icl)<sub>844</sub>, (Icm)<sub>845</sub>, (Icn)<sub>846</sub>, (Ico)<sub>847</sub>, (Icp)<sub>848</sub>, (Icq)<sub>849</sub>, (Icr)<sub>850</sub>, (Ics)<sub>851</sub>, (Ict)<sub>852</sub>, (Icu)<sub>853</sub>, (Icv)<sub>854</sub>, (Icw)<sub>855</sub>, (Icx)<sub>856</sub>, (Icy)<sub>857</sub>, (Icz)<sub>858</sub>, (Ica)<sub>859</sub>, (Icb)<sub>860</sub>, (Icc)<sub>861</sub>, (Icd)<sub>862</sub>, (Ice)<sub>863</sub>, (Icf)<sub>864</sub>, (Icg)<sub>865</sub>, (Ich)<sub>866</sub>, (Ici)<sub>867</sub>, (Icj)<sub>868</sub>, (Ick)<sub>869</sub>, (Icl)<sub>870</sub>, (Icm)<sub>871</sub>, (Icn)<sub>872</sub>, (Ico)<sub>873</sub>, (Icp)<sub>874</sub>, (Icq)<sub>875</sub>, (Icr)<sub>876</sub>, (Ics)<sub>877</sub>, (Ict)<sub>878</sub>, (Icu)<sub>879</sub>, (Icv)<sub>880</sub>, (Icw)<sub>881</sub>, (Icx)<sub>882</sub>, (Icy)<sub>883</sub>, (Icz)<sub>884</sub>, (Ica)<sub>885</sub>, (Icb)<sub>886</sub>, (Icc)<sub>887</sub>, (Icd)<sub>888</sub>, (Ice)<sub>889</sub>, (Icf)<sub>890</sub>, (Icg)<sub>891</sub>, (Ich)<sub>892</sub>, (Ici)<sub>893</sub>, (Icj)<sub>894</sub>, (Ick)<sub>895</sub>, (Icl)<sub>896</sub>, (Icm)<sub>897</sub>, (Icn)<sub>898</sub>, (Ico)<sub>899</sub>, (Icp)<sub>900</sub>, (Icq)<sub>901</sub>, (Icr)<sub>902</sub>, (Ics)<sub>903</sub>, (Ict)<sub>904</sub>, (Icu)<sub>905</sub>, (Icv)<sub>906</sub>, (Icw)<sub>907</sub>, (Icx)<sub>908</sub>, (Icy)<sub>909</sub>, (Icz)<sub>910</sub>, (Ica)<sub>911</sub>, (Icb)<sub>912</sub>, (Icc)<sub>913</sub>, (Icd)<sub>914</sub>, (Ice)<sub>915</sub>, (Icf)<sub>916</sub>, (Icg)<sub>917</sub>, (Ich)<sub>918</sub>, (Ici)<sub>919</sub>, (Icj)<sub>920</sub>, (Ick)<sub>921</sub>, (Icl)<sub>922</sub>, (Icm)<sub>923</sub>, (Icn)<sub>924</sub>, (Ico)<sub>925</sub>, (Icp)<sub>926</sub>, (Icq)<sub>927</sub>, (Icr)<sub>928</sub>, (Ics)<sub>929</sub>, (Ict)<sub>930</sub>, (Icu)<sub>931</sub>, (Icv)<sub>932</sub>, (Icw)<sub>933</sub>, (Icx)<sub>934</sub>, (Icy)<sub>935</sub>, (Icz)<sub>936</sub>, (Ica)<sub>937</sub>, (Icb)<sub>938</sub>, (Icc)<sub>939</sub>, (Icd)<sub>940</sub>, (Ice)<sub>941</sub>, (Icf)<sub>942</sub>, (Icg)<sub>943</sub>, (Ich)<sub>944</sub>, (Ici)<sub>945</sub>, (Icj)<sub>946</sub>, (Ick)<sub>947</sub>, (Icl)<sub>948</sub>, (Icm)<sub>949</sub>, (Icn)<sub>950</sub>, (Ico)<sub>951</sub>, (Icp)<sub>952</sub>, (Icq)<sub>953</sub>, (Icr)<sub>954</sub>, (Ics)<sub>955</sub>, (Ict)<sub>956</sub>, (Icu)<sub>957</sub>, (Icv)<sub>958</sub>, (Icw)<sub>959</sub>, (Icx)<sub>960</sub>, (Icy)<sub>961</sub>, (Icz)<sub>962</sub>, (Ica)<sub>963</sub>, (Icb)<sub>964</sub>, (Icc)<sub>965</sub>, (Icd)<sub>966</sub>, (Ice)<sub>967</sub>, (Icf)<sub>968</sub>, (Icg)<sub>969</sub>, (Ich)<sub>970</sub>, (Ici)<sub>971</sub>, (Icj)<sub>972</sub>, (Ick)<sub>973</sub>, (Icl)<sub>974</sub>, (Icm)<sub>975</sub>, (Icn)<sub>976</sub>, (Ico)<sub>977</sub>, (Icp)<sub>978</sub>, (Icq)<sub>979</sub>, (Icr)<sub>980</sub>, (Ics)<sub>981</sub>, (Ict)<sub>982</sub>, (Icu)<sub>983</sub>, (Icv)<sub>984</sub>, (Icw)<sub>985</sub>, (Icx)<sub>986</sub>, (Icy)<sub>987</sub>, (Icz)<sub>988</sub>, (Ica)<sub>989</sub>, (Icb)<sub>990</sub>, (Icc)<sub>991</sub>, (Icd)<sub>992</sub>, (Ice)<sub>993</sub>, (Icf)<sub>994</sub>, (Icg)<sub>995</sub>, (Ich)<sub>996</sub>, (Ici)<sub>997</sub>, (Icj)<sub>998</sub>, (Ick)<sub>999</sub>, (Icl)<sub>1000</sub>, (Icm)<sub>1001</sub>, (Icn)<sub>1002</sub>, (Ico)<sub>1003</sub>, (Icp)<sub>1004</sub>, (Icq)<sub>1005</sub>, (Icr)<sub>1006</sub>, (Ics)<sub>1007</sub>, (Ict)<sub>1008</sub>, (Icu)<sub>1009</sub>, (Icv)<sub>1010</sub>, (Icw)<sub>1011</sub>, (Icx)<sub>1012</sub>, (Icy)<sub>1013</sub>, (Icz)<sub>1014</sub>, (Ica)<sub>1015</sub>, (Icb)<sub>1016</sub>, (Icc)<sub>1017</sub>, (Icd)<sub>1018</sub>, (Ice)<sub>1019</sub>, (Icf)<sub>1020</sub>, (Icg)<sub>1021</sub>, (Ich)<sub>1022</sub>, (Ici)</p>	

<p>fluoresceinated microbeads, Rhodamine and fluorescent derivatives thereof including Rhodamine Green™, including the tetramethylrhodamines, X-rhodamines and Texas Red derivatives, and Rhodol Green™, coupled to amine groups using the isocyanate, succinimidyl ester or dichlorotriazinyl-reactive groups, and wherein Lig <sup>1</sup><sub>2</sub>, L<sub>1</sub> is selected from:</p> <p>xanthine-like structures</p> <p>adenosine-like structures;</p> <p>ethanolamine-like structures; and</p> <p>oxypropanolamine-like structures; wherein linking functionality L<sub>1</sub> is amine; and wherein linker L<sub>1</sub> is selected from branched and straight chain C<sub>1-50</sub> alkyl, C<sub>6-50</sub> cycloalkyl or aryl and combinations thereof, optionally comprising one or more heteroatoms O and optionally substituted by C<sub>1-12</sub> aliphatic; or for xanthine-like structures L<sub>1</sub> is also selected from a single bond, with the proviso that when Lig is XAC, ie in Lig.a when each of R.a<sup>1</sup> and R.a<sup>2</sup> is propyl, R.a<sup>3</sup> is H and R.a<sup>4</sup> is -Ph-CH<sub>2</sub>-CONH(CH<sub>2</sub>)<sub>2</sub>NH<sub>2</sub>, and L<sub>1</sub> is a single bond FI is not BODIPY™ 630/650 X<sub>2</sub>, or</p> <p>b) when Lig is ABEA, ie m is 4 and L<sub>1</sub> is a single bond FI is not BODIPY™ 630/650 X.</p>	<p>[0170]</p>	
<p>[0171]</p>		

<p>69 (withdrawn). A kit comprising a Compound of formula I or I' as hereinbefore defined in Claim 47 associated with information relating to its pharmacological properties in the form of Spectral Properties given as Excitation Max and Emission Max, Fluorescence Lifetime and Emission quantum yield and Pharmacology defined in terms of cells expressing a GPCR receptor as hereinbefore defined or expressing an intracellular cyclic nucleotide phosphodiesterase, or a drug transporter as hereinbefore defined and given as the Inhibition or Antagonism of receptor binding or of receptor functionality together with a value for the Inhibition (<math>PK_i</math>) or Antagonism (<math>PK_a</math>) binding constants, and optionally together with fluorescent images of the pharmacological binding in single living cells illustrating the defined inhibition or antagonism, preferably the pharmacological properties are given as <math>EC_{50}</math> values for agonist stimulated – or <math>PK_i</math> values for antagonism of agonist stimulated second messenger generation, or substrate <math>K_m</math> values or antagonist <math>K_i</math> values for stimulation or inhibition of intracellular enzymes or drug transporters.</p>	<p>[0157]</p>	
	<p>[0158, lines 17-21]</p>	

<p>70 (currently amended). Compound of formula IV or IV' or library thereof as hereinbefore defined in Claim 59 useful for linking to any suitable tag of formula V or V' as hereinbefore defined in Claim 59,</p> <p>wherein the linker moiety is of formula</p> $-Aq_b-R_b-J''$ <p>wherein each of J and J'' is amine or -O-, A is <math>-CH_2CH_2O-</math>, <math>q_b</math> is 1-30 or 31 to 300 and <math>R_b</math> is <math>-CH_2CH_2-</math></p> <p>or of formula</p> $-JAq_b-R_b(A''J'')-J''$ <p>wherein each of J, J' and J'' independently is amine, -O- or a single bond, <math>q_b</math> is 1, 2 or 3-30 or 31 to 300 and A is <math>-CH_2CH_2O-</math> or <math>-HNCH_2CO-</math> or <math>q_b</math> is 1 and A is <math>-C(O)-</math> or <math>-(CH_2)_{1-8}-</math> or <math>q_b</math> is 0, <math>R_b</math> is <math>-CH_2CH_2-</math>, <math>q_b</math> is 0 or <math>q_b</math> is 1 and A' is <math>-CH_2-</math> and <math>q_b</math> is 0</p> <p>preferably</p> $O(CH_2CH_2O)_{q_b}CH_2CH_2NH_2-O(CH_2CH_2O)_{q_b}CH_2CH(CH_2NH_2)NH_2$ $O(CH(CH_2NH_2)NH_2-CH(CH_2NH_2)NH_2-C(O)NH_2-(CH_2)_{1-8}-O-(HNCH_2CO)_{1-3}-(\text{---}g^{1,1,3,3}\text{---}))$	[0179]	
<p>71 (withdrawn and currently amended). Fluorophore linker of formula V' or library thereof as</p>		

<p>hereinbefore defined in Claim 59 wherein the linker moiety is of formula</p> $J-Aq_L-R_q-J''$ <p>wherein each of J and J'' is amine or —O—, A is <math>\text{CH}_2\text{CH}_2\text{O}</math>, <math>q_L</math> is 1-30 or 31 to 300 and <math>R_q</math> is <math>\text{CH}_2\text{CH}_3</math></p> <p>or of formula</p> $J-Aq_L-R_q(A^1J'')J''$ <p>wherein each of J, J' and J'' independently is amine, —O— or a single bond, <math>q_L</math> is 1, 2 or 3-30 or 31 to 300 and A is <math>\text{CH}_2\text{CH}_2\text{O}</math> or <math>\text{HNCH}_2\text{CO}</math> or <math>q_L</math> is 1 and A is <math>\text{C(O)}</math> or <math>\text{(CH}_2\text{)}_{1-8}</math> or <math>q_L</math> is 0, <math>R_q</math> is <math>\text{CH}</math> or <math>\text{CH}_2\text{CH}_3</math>, <math>q_L</math> is 0 or <math>q_L</math> is 1 and <math>A^1</math> is <math>\text{CH}_2</math> and <math>q_{L'}</math> is 0</p> <p>preferably</p> $\text{O}(\text{CH}_2\text{CH}_2\text{O})_{q_L}\text{CH}_2\text{CH}_2\text{NH}_2\text{O}(\text{CH}_2\text{CH}_2\text{O})_{q_L}\text{CH}_2\text{CH}(\text{CH}_2\text{NH})\text{NH}_2$ $\text{OCH}(\text{CH}_2\text{NH})\text{NH}_2\text{CH}(\text{CH}_2\text{NH})\text{NH}_2\text{C(O)NH}_2(\text{CH}_2)_{1-8}\text{ or }(\text{HNCH}_2\text{CO})_{1-3} (=g^{1'4,1,3'})$		
<p>72 (withdrawn and currently amended). Kit comprising ligand precursors, linker precursors and tag precursors of formulae IV, IV', V, V' and/or VI as hereinbefore defined in Claim 59 for preparing a library of compounds of formula I (<math>\text{Lig}_L</math>)<math>_m</math> L (<math>\text{Tr Tag}</math>)<math>_n</math> (<math>\text{Tr L}</math>) (<math>\text{L Lig}</math>)<math>_p</math> and salts thereof wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers</p>	<p>[0181]</p> <p>[0173]</p> <p>[0114]</p>	


<p>comprising one or a plurality of same or different ligand moieties Lig each linked to one or a plurality of same or different tag moieties Tag via same or different linker moieties L and same or different linking site or linking functionality <math>J_I</math> and <math>J_L</math></p> <p>wherein Lig comprises a GPCR ligand, an inhibitor of an intracellular enzyme or a substrate or inhibitor of a drug transporter;</p> <p>L is selected from a <u>single or double bond</u>, -O-, -S-, amine, COO-, amide, -NN- hydrazine; and saturated or unsaturated, substituted or unsubstituted <math>C_{1-60}</math> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any <math>C_{1-20}</math> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amino, hydrazine, oxo, cyano and carbonyl and combinations thereof, and L may be monomeric, oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300;</p> <p>Tag is any tagging substrate;</p> <p>m are each independently selected from a whole number integer from 1 to 3;</p> <p>p is 0 to 3</p> <p>wherein one or more of each -Tag in one or more or each library compound is a fluorophore entity -Fl, whereby the library comprises compounds of which one or more or all of which <u>compounds</u> are of formula I'</p> <p><math>(Lig)_m L (J_I Fl)_m (J_L L)_m</math></p>	<p>[0045]</p>	
<p>[0015]</p>		
<p>[0016]</p>		
<p>[0017]</p>		
<p>[0018]</p>		
<p>[0027]</p>		

<p>characterised in that wherein linking is at same or different linking sites in compounds comprising different Lig, L<sub>1</sub>, L, J<sub>1</sub> and/or - Tag and is at different linking sites in compounds comprising same Lig, L<sub>1</sub>, L, J<sub>1</sub> and/or - Tag</p> <p><del>with the proviso that when Lig is GGP12177 and L is 1,1,4,4-tetramethyl-betahistine C(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>NH, FI is not BODIPY@-FI, or when L is C(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>NHCSNH then FI is not FITC, eosin or erythrosin wherein the or each FI is selected from a red, near ir or blue dye.</del></p>	<p>[0018]</p>	
<p>73 (withdrawn and currently amended). A library of fluorescent ligands of formula I or I' or a kit comprising a compound thereof as hereinbefore defined in Claim 47 for visualising receptors or receptor binding, assessing pharmacological properties of the fluorescent ligand, in high throughput screening of novel chemical entities that bind to the target receptor, in inhibiting an</p>	<p>[0182, lines 1-10]</p>	



intracellular enzyme or inhibiting a drug transporter or a substrate of a drug transporter, in studying drug transport or drugs suitable for transport or in distinguishing healthy or diseased tissue.		
74 (withdrawn and currently amended). A library of fluorescent ligands of formula I or I' or a <del>kit comprising a</del> compound thereof <del>herebefore</del> defined in claim 47 or 64 for use in a method for receptor binding or inhibition, intracellular enzyme inhibition or drug transport or inhibition and visualisation comprising contacting <del>the</del> library or a compound thereof <del>as defined in claim 47</del> with a sample comprising live cell material comprising GPCRs, intracellular enzymes or drug transporters in manner to facilitate binding or inhibition thereof or transport thereby, and detecting changes in fluorescence or location thereof.	[0183]	
75. (withdrawn and currently amended). A library of fluorescent ligands of formula I or I' or a <del>kit comprising a</del> compound thereof for use as claimed in claim 74 wherein the library or compound thereof is a fluorescent ligand(s) which has affinity such that it binds permanently; semi-permanently or transiently and remains bound when unbound ligand is washed away.	[0172, lines 5-81]	Pg. 42, lines 4-6
76. (withdrawn and currently amended). A library of fluorescent ligands of formula I or I' or a <del>kit comprising a</del> compound thereof for use as claimed in claim 74 wherein detecting a change in fluorescence is by means of confocal microscopy or fluorescence correlation spectroscopy.	[0182]	Pg.2, lines 1-2; pg. 50, lines 15-16 and pag. 51, lines 20-28

<p>77. (withdrawn and currently amended). A library of fluorescent ligands of formula I or I' or a <del>kit comprising a</del> compound thereof for use as claimed in claim 74 wherein the library or compound thereof comprises fluorescent ligand agonist(s) which maintains its binding affinity and functional activity <u>or is an antagonist which maintains its binding affinity on linking or when linked to fluorescent moiety II.</u></p>	<p>[0172, lines 1-5]</p>	<p>Pg. 42, lines 1-4</p>
<p>78. (withdrawn and currently amended). A kit comprising a library or a compound of formula I or I' as claimed in claim 47 or 64 and a target therefor provided as cell derived material selected from a cell line, expressing a GPCR, intracellular enzyme or drug transporter, membrane containing these proteins derived from such a cell line, solubilised receptor, enzyme or drug transporter or GPCR array from that cell line.</p>	<p>[0204, lines 1-5] [0185, lines 3-6]</p>	
<p>79. (withdrawn). Kit as claimed in Claim 78 wherein the cell derived material is provided in one of three forms: (1) from cells expressing a green fluorescent protein tagged receptor, intracellular enzyme or drug transporter; (2) from cells expressing an epitope tag for a commercially available fluorescent antibody or (3) a wild-type protein for which a specific fluorescent antibody is also provided.</p>	<p>[0204, lines 5-end]</p>	

80-82. (canceled).	
<p>83. (withdrawn and currently amended). Library as claimed in Claim 59-55 comprising a plurality of compounds of the formula</p> <p style="text-align: center;">  </p> <p>wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers</p> <p>wherein F1 is selected from dyes in particular including fluorescein, fluorescein derivatives including FITC, and fluorescein like molecules including Oregon Green™ and its derivatives, Texas-red™, 7-nitrobenz-2-oxa-1,3-diazole (NBD) and derivatives thereof, coumarin and derivatives, naphthalene including derivatives of dansyl chloride or its analogues or derivatives, Cascade Blue™, EvobBlue and fluorescent derivatives thereof, pyrenes and pyridyloxazole derivatives, the cyanine dyes, the dyamines (DY dyes and ATTQ dyes) and fluorescent derivatives thereof, the Alexafluor dyes and derivatives, BODI dyes including the commercially available Bodipy™ dyes, erythrosin, eosin, pyrenes, anthracenes, acridines, fluorescent phycoobiliproteins and their conjugates and fluoresceinated microbeads, Rhodamine and fluorescent derivatives thereof including Rhodamine Green™ including the tetramethylrhodamines, X-rhodamines and Texas Red derivatives, and Rhodol Green™, coupled to amine groups using the isocyanate, succinimidyl ester or dihydrotriazinyl reactive groups,</p>	

and

wherein  $\text{Lig}_1, \text{L}_1, \text{L}_2$  is selected from the formulae  $\text{Lig}_a$ ,  $\text{Lig}_b$ ,  $\text{Lig}_c$  and  $\text{Lig}_d$  wherein:

$\text{Lig}_a$  comprises linking functionality  $\text{L}_1$  which is amine, and is of the formula, in either of the following forms given:

$\text{Lig}_a^1$



wherein  $\text{Ra}^4$  comprises linking functionality  $\text{L}_1$  and  $\text{L}_2$  which is amine;

$\text{X}^1$  and  $\text{X}^2$  are each  $\text{O}$ ;


$\text{Ra}^3$  is  $\text{H}$ ;

each of  $\text{Ra}^1$  and  $\text{Ra}^2$  is n-propyl;

$\text{Ra}^4$  is p-substituted phenyl wherein the substituent is heteroalkyl amide amine; and includes  $\text{L}$  which is a single bond or is  $\text{C}_{1-50}$  alkyl optionally substituted by  $\text{C}_1$  alkyl and including

the formula  $-(CH_2)_n$  where n is 3 to 8, optionally including one or more heteroatoms -O;

Lig.b comprises linking functionality  $J_L$  which is amine, and is



wherein ring substituents  $X.b^1$  and  $X.b^2$  are each OH;

ring heteroatom  $X.b^3$  is -O-;


$Rb^1$  is  $CONHEt$  or  $CH_2OH$ ;

and each of  $R.b^2$  and  $R.b^3$  is H;

$Rb^4$  is  $H$ ;

$Rb^5$  comprises linking functionality  $J_r$  which is amino, and linker  $L.b$  selected from saturated  $C_{1-12}$  aliphatic and  $C_{6-24}$  aromatic, optionally substituted by one or more  $C_1$  alkyl and optionally including one or more heteroatoms O or cyclic groups;

Lig.c comprises linking functionality  $J_L$  which is amine and is




as a racemate or as one of its optically active isomers wherein \* indicates an optically active centre,

Rc<sup>1</sup> is m-, p-dihydroxyphenyl; and




Rc<sup>2</sup> comprises linking functionality Jr which is amine, and linker L<sub>c</sub> which is selected from C<sub>1-12</sub> straight chain alkyl, C<sub>6-12</sub> cycloalkyl or aryl and combinations thereof optionally comprising one or more heteroatoms O and optionally substituted by C<sub>1</sub> aliphatic;

or Ligd comprises a linking functionality Jr which is amine and is



as a racemate or as one of its optically active isomers wherein \* indicates an optically active centre,

Rd<sup>1</sup> is selected from the structures




and a substituted  $C_{1-20}$  spiro aromatic ring system comprising a single aromatic ring and a heteroaryl and optionally halo substituted; and


$Rd^2$  comprises linking functionality  $J_1$  which is amine, and linker  $L_d$  which is selected from  $C_{1-12}$  straight chain alkyl,  $C_{6-12}$  cycloalkyl or aryl and combinations thereof optionally comprising one or more heteroatoms O and optionally substituted by  $C_1$  aliphatic; or  $Rd^2$  is  $C_{1-6}$  straight chain alkyl including ether O and substituted by  $C_{6-10}$  aryl which is OH and oxo substituted and comprises linker  $L_d$  as hereinbefore defined.

84. (withdrawn). Library as claimed in claim 83 wherein

R.a<sup>4</sup>, R.b<sup>5</sup> or R.c<sup>2</sup> or R.d<sup>2</sup> comprises linking functionality J<sub>r</sub> which is amino, and linker L.a, L.b, L.c or L.d selected from (CH<sub>2</sub>)<sub>m</sub> wherein m is 3, 4, 6 or 8 or is in the range 3 to 8 or 2 to 12 optionally including one or more substituents C<sub>1</sub>, or J<sub>L</sub> L J<sub>r</sub> is mono or polyethylene glycol diamine, or L.a is a single bond; or  
 R.c<sup>2</sup> or R.d<sup>2</sup> comprises linking functionality J<sub>r</sub> which is amino, and linker L.c or L.d selected from C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>Ph and mono amino methane or the structure



or R.d<sup>2</sup> comprises the following OH substituted aryl structure wherein linking functionality J<sub>L</sub> is shown as amine, L.d is as hereinabove defined and includes J<sub>r</sub> which is amine:



85. (canceled).


86. (withdrawn and currently amended). Library as claimed in Claim 83-47 wherein F1 is selected from Texas Red™, Cy5.5 or Cy5 or analogues thereof, DY-630, DY-640, DY-650 or DY-655 or analogues thereof, ATTO 655 or ATTO 680 or analogues thereof, Evoblue 30 or

[0117]



analogues thereof, Alexa 647 or analogues thereof, BODIPY 630/650 X and analogues thereof  
including BODIPY 630/650 X.


87. (withdrawn and currently amended). Library as claimed in claim 86 comprising a compound selected from the following structures wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers:




XAC - BODIPY 630/650 X

[0225]

Pg. 59, lines 1-3




ABA-BY630



[0237]

Pg. 65, lines 1-3

ABEA-BY630




APEA-BY 630

[0239]


Pg. 66, lines 2-3

[0245]

Pg. 67; lines 1-3




ABIPeA - BY630



And

[0249]


Pg. 68; scheme  
4



[0249] &  
[0250]

Pg. 68; scheme  
4 and pg. 68,  
lines 1-3


Salmeterol BY 630/650



[0251]

Pg. 59, lines 15-  
20


Clenbuterol BY 630/650



CGP12177-BY 630/650

[252]

Pg. 70, line 5




[0252]

Pg. 70, line 5

Propranolol BY630/650

[0252]


Pg. 70, line 10



[252]

Pg. 70, line 10

ICI118551-BY630/650



[0252]

Pg. 70, line 10

Alprenolol-BY630/650

88. (currently amended). Compound as claimed in Claim 67 of the formula

$$\text{Fig. 1. } \text{L}_1\text{F}$$

wherein any optically active fluorescent ligand is present as a racemate or as one of its optically



active isomers

wherein  $I_1$  is selected from dyes in particular including fluorescein, fluorescein derivatives including FITC, and fluorescein-like molecules including Oregon Green™ and its derivatives, Texas red™, 7-nitrobenz-2-oxa-1,3-diazole (NBD) and derivatives thereof, coumarin and derivatives, naphthalene including derivatives of dansyl chloride or its analogues or derivatives, Cascade Blue™, Evyoblu and fluorescent derivatives thereof, pyrenes and pyridyloxazole derivatives, the cyanine dyes, the dyes (DY dyes and ATTO dyes) and fluorescent derivatives thereof, the Alexafluor dyes and derivatives, BDI dyes including the commercially available Bodipy™ dyes, erythrosin, eosin, pyrenes, anthracenes, acridines, fluorescent phycoerythrin and their conjugates and fluoresceinated microbeads, Rhodamine and fluorescent derivatives thereof including Rhodamine Green™ including the tetramethylrhodamines, X-rhodamines and Texas Red derivatives, and Rhodol Green™, coupled to amine groups using the isocyanate, succinimidyl ester or diethylphosphoryl reactive groups; and

wherein  $I_2$ ,  $I_3$  is selected from the formulae  $I_2a$ ,  $I_2b$ ,  $I_2c$  and  $I_2d$  wherein:

$I_2a$  comprises linking functionality  $I_2$  which is amine, and is of the formula, in either of the following forms given:

$I_2a$   
 $I_2m$



wherein  $Ra^4$  comprises linking functionality  $J_L$  and  $J_T$  which is amine;


$X^1$  and  $X^2$  are each O;

$Ra^3$  is H;

each of  $Ra^1$  and  $Ra^2$  is n-propyl;



$Ra^4$  is p-substituted phenyl wherein the substituent is heteroalkyl amine; and includes L which is a single bond or is  $C_{1-50}$  alkyl optionally substituted by  $C_1$  alkyl and including the formula  $-(CH_2)_n$  where n is 3 to 8, optionally including one or more heteroatoms -O;

Lig b comprises linking functionality  $J_L$  which is amine, and is







wherein ring substituents  $X.b^1$  and  $X.b^2$  are each OH;

ring heteroatom  $X.b^3$  is -O-;

<p>Rb<sup>1</sup> is CONHEt or CH<sub>2</sub>OH; and each of R.b.<sup>2</sup> and R.b.<sup>3</sup> is H; Rb<sup>4</sup> is H; Rb<sup>5</sup> comprises linking functionality J<sub>r</sub> which is amino, and linker L.b selected from saturated C<sub>1-12</sub> aliphatic and C<sub>6-24</sub> aromatic, optionally substituted by one or more C<sub>1</sub> alkyl and optionally including one or more heteroatoms O or cyclic groups;</p>	
<p>Lig.c comprises linking functionality J<sub>L</sub> which is amine and is as a racemate or as one of its optically active isomers wherein * indicates an optically active centre,    Rc<sup>1</sup> is m-, p-dihydroxyphenyl; and  Rc<sup>2</sup> comprises linking functionality J<sub>r</sub> which is amine, and linker L.c which is selected from C<sub>1-12</sub> straight chain alkyl, C<sub>6-12</sub> cycloalkyl or aryl and combinations thereof optionally comprising one or more heteroatoms O and optionally substituted by C<sub>1</sub> aliphatic;</p>	
<p>or Lig.d comprises a linking functionality J<sub>L</sub> which is amine and is  </p>	

as a racemate or as one of its optically active isomers wherein \* indicates an optically active centre,

Rd<sup>1</sup> is selected from the structures




and a substituted C<sub>1-20</sub> spiro aromatic ring system comprising a single aromatic ring and a heteroaryl and optionally halo substituted; and


Rd<sup>2</sup> comprises linking functionality L<sup>1</sup> which is amine, and linker L<sup>2</sup> which is selected from C<sub>1-12</sub> straight chain alkyl, C<sub>6-12</sub> cycloalkyl or aryl and combinations thereof optionally comprising one or more heteroatoms O and optionally substituted by C<sub>1</sub> aliphatic; or Rd<sup>2</sup> is C<sub>1-6</sub> straight chain alkyl including ether O and substituted by C<sub>6-10</sub> aryl which is OH and oxo substituted and

comprises linker L.d as hereinbefore defined,  
with the proviso that the compound is not a compound excluded in Claim 18.

89. (currently amended). Compound as claimed in Claim 88 wherein R.a<sup>4</sup>, R.b<sup>5</sup> or R.c<sup>2</sup> or R.d<sup>2</sup> comprises linking functionality J<sub>r</sub> which is amino, and linker L.a, L.b, L.c or L.d selected from (CH<sub>2</sub>)<sub>m</sub> wherein m is 3, 4, 6 or 8 or is in the range 3 to 8 or 2 to 12 optionally including one or more substituents C<sub>1</sub>, or J<sub>L</sub>, L J<sub>r</sub> is mono or polyethylene glycol diamine, or L.a is a single bond; or  
R.c<sup>2</sup> or R.d<sup>2</sup> comprises linking functionality J<sub>r</sub> which is amino, and linker L.c or L.d selected from C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>Ph and mono amino menthane or the structure



or Rd<sup>2</sup> comprises the following OH substituted aryl structure wherein linking functionality J<sub>L</sub> is shown as amine, Ld is as hereinabove defined and includes J<sub>r</sub> which is amine:



with the proviso that when  $Hiz-Lig$  is XAC ie in Lig.a when each of  $R.a^1$  and  $R.a^2$  is propyl,  $R.a^3$  is H and  $R.a^4$  is  $-Ph-OCH_2CONH(CH_2)_2NH_2$ , and L is a single bond FI is not BODIPY™ 630/650 X; or


b) when Lig is ABEA, ie m is 4 and L is a single bond FI is not BODIPY™ 630/650 X.

90. (canceled)

91. (currently amended). Compound as claimed in Claim 88-64 wherein FI is selected from Texas Red™, Cy5.5 or Cy5 or analogues thereof, DY-630, DY-640, DY-650 or DY-655 or analogues thereof, ATTO 655 or ATTO 680 or analogues thereof, EvoxBlue 30 or analogues thereof, Alexa 647 or analogues thereof, BODIPY 630/650-X and analogues thereof including BODIPY 630/650-X.

[0117]

92. (withdrawn and currently amended). Compound selected from the structures wherein any optically active fluorescent ligand is present as a racemate or as one of its optically active isomers:





ABA-BY630


[0225]

Pg. 57, lines 1-3


Docket No. Q111431

	[0239]	Pg. 59, lines 1-3
<p data-bbox="585 125 606 243">APEA-BY 630</p> 	[0245]	Pg. 67, lines 1-3
<p data-bbox="181 125 202 276">ABIPEA - BY630</p>	[0249]	Pg. 68, scheme 4





And Salmeterol derivative – BY 630/650



[0249]

Pg. 68; scheme

[0250]

4 and pg. 69,

lines 1-3

[251]


Pg. 69, lines 15-

20

[0252]

Pg. 70, line 5

Salmeterol BY 630/650



[0252]


Pg. 70, line 5

[0252]

Pg. 70, line 10


Clenbuterol BY 630/650

[0252]




CGP12177-BY 630/650


Docket No. Q111431



Propranolol BY630/650




ICI118551-BY630/650




Alprenolol-BY630/650

and optionally additionally

Docket No. Q111431

~~XAC-BODIPY-630/650-X~~

of



ABEA-BY630.

Docket No. Q111431



R<sub>a</sub><sup>4</sup> is selected from a heteroatom O, S or substituted or unsubstituted amine or saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like;


preferably

R<sub>a</sub><sup>4</sup> is selected from optionally substituted aryl, cycloalkyl, alkyl, ketone, (di)amine, (di)amide, more preferably optionally substituted alkoxy, cycloalkyl, amine, amide, carboxylic acid or optionally o-, m- or p- substituted phenyl wherein substituents include aryl, alkyl, cycloalkyl, heteroaryl or heteroalkyl, amine, amide, carboxyl, carbonyl etc, for example is cyclohexyl, cyclopentyl, ethoxy, (CH<sub>2</sub>)<sub>2</sub>PhPh, CH<sub>2</sub>Ph, CONH(CH<sub>2</sub>)<sub>n</sub>CONH, CH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NH, CH<sub>2</sub>PhNHCOCH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>OCOCH<sub>2</sub>, succinimidyl ester, NHCOCH<sub>2</sub>, CH<sub>2</sub>(CH<sub>3</sub>)NCOCH<sub>2</sub>, H<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>, H<sub>2</sub>N(CH<sub>2</sub>)<sub>8</sub>NHCOCH<sub>2</sub>, H<sub>2</sub>NNHCOCH<sub>2</sub>, CH<sub>2</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>, HOPhCH<sub>2</sub>N(CH<sub>2</sub>)<sub>3</sub>HOAc(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>, heterocyclic-(CH<sub>2</sub>)<sub>4</sub>CONH(CH<sub>2</sub>)<sub>2</sub>NHCOCH<sub>2</sub>, heterocyclic-NHCON(heterocyclic)COCH<sub>2</sub> and the like;

or Lig-a- is of the formula Lig-a<sup>2</sup>-

[0067]





[0069]

[0070]

[0071]

wherein each of  $C_{A1}$  and  $C_{A2}$  is independently selected from aryl, heteroaryl, cycloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring  $C=C$  group;


Each of up to seven  $R_a^5$  is a substituent of a ring carbon or a ring heteroatom and:

[0072]

is independently selected from H, halo, hydroxy, thiol, amine,  $COOH$ , hydrazine, cyano, saturated or unsaturated, substituted or unsubstituted  $C_{1-20}$  branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any  $C_{1-12}$  aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, such as  $=O$ ,  $OCH_3$ ,  $CH_2Ph(OCH_3)_2$ ,  $O(CH_2)_3CON(CH_3)_2$ , hex,

[0073]

<p> <math>N(CH_2CH_2OH)_2</math>, c,hex, <math>COOCH_2CH_3</math>, <math>CH_2CH_3</math>;  or any two or more of <math>R.a^5</math> form a one, two or three ring fused cyclic structure, preferably comprising a fused 3 ring aryl, 5-heterocyclic, 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic <math>Lig.a^2</math> structure;  and <math>R.a^6</math> is a moiety as defined for <math>R.a^5</math> above;  and <math>L.a-</math> is as hereinbefore defined for <math>-L-</math> and is suitably of formula <math>-L.L-</math> or <math>-L.Ll-</math> as hereinbefore defined, more preferably is selected from a single bond, amino acid or amide such as a peptide or polypeptide for example gly or gly<sub>n</sub>, alkyl of formula <math>-(CH_2)_n</math> where n is 3 to 8, preferably 3, 4 or 6, optionally including one or more heteroatoms or unsaturated groups, such as <math>-O-</math> or <math>-S-</math> or <math>-CH=CH-</math> and the like: </p> <p><math>Lig.b</math> is suitably of the formula <math>Lig.b</math></p>	<p>[0075]</p> <p>[0076] [0077]</p>
--	--



wherein ring substituents  $X.b^1$  and  $X.b^2$  are independently selected from hydrocarbon such as alkyl

or SR<sub>x</sub>, NR<sub>x</sub>2 and OR<sub>x</sub> wherein (each) R<sub>x</sub> is selected from H, C<sub>1-3</sub>alkyl, alkenyl;

ring heteroatom X.b<sup>3</sup> is selected from -S-, -O- and -CH<sub>2</sub>-;

$\text{Rb}^1$  is selected from saturated or unsaturated, substituted or unsubstituted  $\text{C}_{1-4}$  aliphatic,

or C<sub>1-3</sub> alicyclic optionally including one or more heteroatoms N, O, S, P, wherein

substituent(s) are selected from one or more cycloalkyl, heterocyclic, hydroxy, oxo,

halo, amine; preferably R.b<sup>1</sup> comprises a carbonyl substituted by H, alkyl or a linear

or cyclic primary, secondary or tertiary amine, substituted C<sub>1-3</sub> alkyl, cycloalkyl or

amide, more preferably cyclopropyl, or CONHC<sub>1-3</sub>alkyl such as CONHEt or

 $\text{CH}_2\text{OH}$ 

and each of R.b<sup>2</sup> and R.b<sup>3</sup> is selected from H, halo, hydroxy, thiol, amine, COOH,

CHO, hydrazine, cyano or saturated or unsaturated, substituted or unsubstituted C<sub>1</sub>-

<sup>20</sup> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof,

any of which may comprise one or more heteroatoms selected from N, O, S, P;

wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or


[0078]

[0079]

[0082]

<p>alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, preferably from H, halo or hydroxy, preferably H or Cl;</p> <p>Rb<sup>4</sup> is H;</p> <p>-L<sub>b</sub> is as hereinbefore defined for -L<sub>r</sub>, more preferably saturated and unsaturated substituted or unsubstituted C<sub>1-12</sub> aliphatic or C<sub>1-24</sub> aromatic as defined for -L<sub>r</sub> preferably including one or more heteroatoms O, S or N, cyclic or heterocyclic groups, more preferably is of formula -L<sub>1</sub>-I- or -L<sub>1</sub>-II- as hereinbefore defined, most preferably is -(CH<sub>2</sub>)<sub>m</sub> wherein m is 2 to 12, preferably 3, 4, 6 or 8, or is -(Ph-CH<sub>2</sub>CONH)<sub>2</sub> (CH<sub>2</sub>)<sub>2</sub>-;</p>	<p>[0084] [0085]</p>	
<p>Lig c is suitably a non-peptide of the formula</p>		
<p>Lig c                    HOC<sup>*</sup>(R.c<sup>1</sup>)CH<sub>2</sub>NH-R.c<sup>2</sup>-</p> $  \begin{array}{c}  \text{Rc}^1 \\    \\  \text{HO}-\text{C}-\text{CH}_2-\text{N}-\text{Rc}^2 \\    \quad   \\  \text{H} \quad \text{H} \\  \quad \quad \text{Rc}^2 \quad \text{Rc}^2  \end{array}  $ <p>Where * indicates an optically active centre and Wherein R.c<sup>1</sup> is C<sub>6-14</sub> aryl optionally including one or more heteroatoms selected from H, O,</p>		

optionally substituted by OH, Hal eg Cl, NH<sub>2</sub>, NHC<sub>1-3</sub>alkyl, sulphonamide, oxamine (-CONH<sub>2</sub>) and the like, more preferably mono, di or tri substituted phenyl or quinoline wherein substituents include OH, Cl or NH<sub>2</sub>, more preferably m-CH<sub>2</sub>OH, p-OH phenyl, m-,p-dihydroxy phenol or m-,m-dihydroxyphenol, m-,m-diCl, p-NH<sub>2</sub>, phenol, p-OH, m-CONH<sub>2</sub>, phenol or 5-OH, 8-quinoline and the like, such as




[0087]

R<sup>c2</sup> is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub>, preferably C<sub>1-12</sub>, branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any optionally substituted C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thio, halo, amine, hydrazine, oxo, cyano, and the like and combinations thereof;

[0088]

Preferably R<sup>c2</sup> is selected from C<sub>1-6</sub> branched or straight chain aliphatic, C<sub>6-10</sub> araliphatic optionally substituted by OH and optionally including heteroatoms selected from





<p>N,O, preferably including an ether O, such as selected from <math>-(CH_2)_6OCH((CH_2)_3Ph)</math>, <math>CHCH_3((CH_2)_2Ph)</math>, <math>CHCH_3CH_2PhOH</math>, <math>C(CH_3)_2CH_3</math>;</p> <p>-L,c- is as hereinbefore defined for -L- and is suitably of formula -L.L- or -L.LL- as hereinbefore defined, more preferably is selected from C<sub>1-12</sub> alkyl, amide etc;</p>	
<p>Lig.d is suitably a non-peptide of the formula</p> <p>Lig.d R.d<sup>1</sup> OCH<sub>2</sub>C*HOHCH<sub>2</sub>NH-R.d<sup>2</sup>-#</p>	<p>[0091]</p>
 <p>Where * indicates an optically active centre and where # indicates the site of linking to the fluorescent tagging moiety</p> <p>Wherein R.d<sup>1</sup> is saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional</p>	

substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like;

Preferably R, d<sup>1</sup> is substituted or unsubstituted C<sub>1-24</sub> aralkyl or heteroaralkyl, including single ring and fused ring systems with (hetero)aryl or cycloalkyl rings, wherein optional substituents include C<sub>1-6</sub> alkyl, alkoxy, ether, carbonyl, alkenyl, amine, amide each optionally carbonyl, amide, halo or OH substituted, or halo such as chloro or OH, preferably R, d<sup>1</sup> is unsubstituted or substituted alkyl, alkenyl, halo, amine, amide, carbonyl, ketone, ether substituted phenyl or naphthyl, illustrated as follows, most preferably mono-, di-, tri- or tetra substituted mono or polycyclic fused aryl or cycloaryl or heterocycloaryl such as phenyl, carbazole or structures shown below or spiro ring systems, most preferably mono-, di-, tri- or tetra alkoxyalkyl, alkoxyalkoxyalkyl or CF<sub>3</sub> substituted phenyl or unsubstituted or monosubstituted naphthalene or 5,6 ring systems most preferably of the structures:

[0093]

[0094]




R, d<sup>2</sup>

is substituted or unsubstituted amine, saturated or unsaturated, substituted or unsubstituted C<sub>1-12</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, more preferably amine, C<sub>1-6</sub> branched or straight chain alkyl optionally including ether O, and optionally substituted by C<sub>6-10</sub> aryl, for example of the formula:

[0096]





[0097]

i.pr, i.bu,  $\text{CH}_2\text{CH}_2\text{O}$  (m- $\text{CONH}_2$ , p-OH) phenol,  $\text{CH}_2\text{CH}_2\text{O}$  (o- $\text{OCH}_3$ ) phenol

[0098]



-L,d- is as hereinbefore defined for -L- and is suitably of formula -L,L- or -L,II- as hereinbefore defined, more preferably is a single bond or is as hereinbefore defined for -L,a-;





Lig e<sup>1</sup>

[0099]

comprises a cell permeant moiety or is associated with a cell permeant L or FI moiety and is suitably of the formula , in either of the following forms given:

[0100]



wherein	h is selected from		
each optionally substituted by $R.e^3 - R.e^4$ wherein $R.e^1 - R.e^4$ are as $R.a^1 - R.a^4$ defined above or in which $R.e^3$ is $C_{5-9}$ linear or branched alkyl, optionally mono or multi hydroxy or halo substituted or is aryl optionally substituted by alkoxy, sulfonyl and the like eg		[0102]	
		[0103]	
	 	[0104]	
ortho-OEt, meta-SO <sub>2</sub> N	NCH <sub>3</sub>	[0106]	
each X is independently selected from H, =O, -OR, $e^2$ , =N, HN, NR, $e^5$ , HR, $e^6$ , and			

<p>aryl optionally substituted by ether, or X is aryl optionally alkyl or alkoxy substituted such as Ph-ortho-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;</p>	<p>[0107] [0108]</p>	
<p>and</p> <p>where R<sup>e5</sup> is as defined above for R<sup>e1</sup> above or forms a fused cyclic ring together with the adjacent ring N atom; preferably 1 or 2 fused 5 membered cyclic rings;</p> <p>and</p> <p>R<sup>e6</sup> is as defined above for R<sup>e1</sup> above or is selected from optionally substituted phenyl wherein optional substituents include ether such as o-ethoxy or o-propoxy, alkyl, OH and the like, sulphonyl, carbonyl and the like substituted by heterocyclic, or cyclic C<sub>3-8</sub> alkyl such as methyl, piperazinyl, sulphonyl and the like;</p>	<p>[0109]</p>	
<p>or Lig<sup>e2</sup> is of the formula Lig<sup>e2</sup></p>	<p>[0110]</p>	
<p>Lig<sup>e2</sup></p> <p>(h)</p> <p>5,6(h)</p>	<p>[0111]</p>	
<p>Wherein each of C<sub>E1</sub> and C<sub>E2</sub> is independently selected from aryl, heteroaryl, cycloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring – C–C– group;</p>		

<p>Each of up to seven <math>R_e^{11}</math> is a substituent of a ring carbon or a ring heteroatom and: is independently selected from saturated or unsaturated, substituted or unsubstituted <math>C_{1-20}</math> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any <math>C_{1-12}</math> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, such as <math>=O</math>, <math>OCH_3</math>, <math>CH_2Ph</math>, <math>(OCH_3)_2</math>, <math>O(CH_2)_3CON(CH_2)_6hex</math>, <math>N(CH_2CH_2OH)_2</math>, <math>c.hex</math>, <math>COOCH_2CH_3</math>, <math>CH_2CH_3</math>;</p> <p>or any two or more of <math>R_e^{11}</math> form a one, two or three ring fused cyclic structure, preferably comprising a fused 3 ring aryl, 5-heterocyclic, 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic <math>Lig_e^3</math> structure;</p> <p>and <math>R_e^{12}</math> is a moiety as defined for <math>R_e^{11}</math> above;</p> <p>Preferably <math>Lig_e</math> is of the formula <math>Lig_e^1</math> as hereinbefore defined in particular where <math>R_e^2</math> and <math>R_e^3</math> are respectively propyl and butyl;</p> <p><math>-L_e</math> is suitably as hereinbefore defined for <math>-L_a</math>.</p>		
<p>94. (new and withdrawn). Library as claimed in claim 93 wherein the or each FI is selected</p>	<p>[0115]</p>	

<p>from the following dyes: Texas red™, coumarin and derivatives, Cascade Blue™, EvobBlue and fluorescent derivatives thereof, pyrenes and pyridyloxazole derivatives, the cyanine dyes, the dyomics (DY dyes and ATTO dyes) and fluorescent derivatives thereof, the Alexafluor dyes and derivatives, BDI dyes including the commercially available Bodipy™ dyes, pyrenes, anthracenes, acridines, fluorescent phycobiliproteins and their conjugates and fluoresceinated microbeads, and Texas Red derivatives, coupled to amine groups using the isocyanate, succinimidyl ester or dichlorotriazinyl-reactive groups.</p>		
<p>95. (new): Compound which is a tagged non-peptide ligand comprising moiety Lig and L selected from formula Lig-a-L-a' - Lig-e-L.e associated with a Tag which is an entity -Fl wherein -Fl is selected from a red, near ir or blue dye and wherein:</p> <p>Lig-a' is suitably of the formula, in either of the following forms given:</p> <p>Lig-a'-</p>	<p>[0060]</p> <p>[0115]</p> <p>[0061]</p> <p>[0063]</p> <p>[0064]</p>	

<p>Wherein</p> <p><math>X^1</math> and <math>X^2</math> are each independently selected from H, =O, OR, a, NR, a, NHR, ar;</p> <p><math>X^1</math> and <math>X^2</math> are each preferably =O;</p> <p>each of R, a, <math>R, a^1</math>, <math>R, a^2</math> and <math>R, a^3</math> independently is selected from H or C<sub>1-4</sub> linear or branched alkyl, preferably H, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl or isobutyl optionally mono or multi hydroxy or halo substituted, such as CH<sub>2</sub>OH, CH<sub>2</sub>F or CH<sub>2</sub>CHOHCH<sub>2</sub>OH;</p> <p><math>R, a^4</math> is selected from a heteroatom O, S or substituted or unsubstituted amine or saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amino, hydrazine, oxo, cyano, and the like;</p> <p><math>R, a^4</math> is selected from optionally substituted aryl, cycloalkyl, alkyl, ketone, (di)amine, (di)amide, more preferably optionally substituted alkoxy, cycloalkyl, amine, amide, carboxylic acid or optionally o-, m- or p- substituted phenyl wherein</p> <p>preferably</p>	<div data-bbox="777 118 922 776"> </div> <p>[0065]</p>
<p>[0067]</p>	<p>[0066]</p>

substituents include aryl, alkyl, cycloalkyl, heteroaryl or heteroalkyl, amine, amide, carboxyl, carbonyl etc, for example is cyclohexyl, cyclopentyl, ethoxy,  $(\text{CH}_2)_2\text{Ph}$ ,  $\text{CH}_2\text{Ph}$ ,  $\text{CONH}(\text{CH}_2)_n\text{CONH}$ ,  $\text{CH}_2\text{CONH}(\text{CH}_2)_2\text{NH}$ ,  $\text{CH}_2\text{PhNHCOCH}_2$ ,  $\text{CH}_2\text{CH}_2\text{OCOCH}_2$ , succinimyl ester,  $\text{NHCOCH}_2$ ,  $\text{CH}_2(\text{CH}_3)\text{NCOCH}_2$ ,  $\text{H}_2\text{N}(\text{CH}_2)_2\text{NHCOCH}_2$ ,  $\text{H}_2\text{N}(\text{CH}_2)_8\text{NHCOCH}_2$ ,  $\text{H}_2\text{NNHCOCH}_2$ ,  $\text{CH}_2\text{CONH}(\text{CH}_2)_2\text{NHCOCH}_2$ ,  $\text{HOPhCH}_2\text{N}(\text{CH}_2\text{CH}_3\text{HOAc})(\text{CH}_2)_2\text{NHCOCH}_2$ , heterocyclic- $(\text{CH}_2)_4\text{CONH}(\text{CH}_2)_2\text{NHCOCH}_2$ , heterocyclic-NHCON(heterocyclic)COCH<sub>2</sub> and the like;

or Lig-a- is of the formula Lig-a'-



wherein each of C<sub>a1</sub> and C<sub>a2</sub> is independently selected from aryl, heteroaryl, cyloalkyl and

heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring -

C=C- group;

Each of up to seven R-a' is a substituent of a ring carbon or a ring heteroatom and:

is independently selected from H, halo, hydroxy, thiol, amine, COOH, hydrazine, cyano, saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain


[0069]

[0070]

[0071]

<p>aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, such as =O, OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>3</sub>CON(CH<sub>3</sub>)<sub>2</sub>.hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>.c.hex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>;</p> <p>or any two or more of R.a<sup>5</sup> form a one, two or three ring fused cyclic structure, preferably comprising a fused 3 ring aryl, 5-heterocyclic, 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.a<sup>2</sup> structure;</p> <p>and R.a<sup>6</sup> is a moiety as defined for R.a<sup>5</sup> above;</p> <p>and -L.a- is as hereinbefore defined for -L- and is suitably of formula -L.I- or -L.II- as hereinbefore defined, more preferably is selected from a single bond, amino acid or amide such as a peptide or polypeptide for example gly or gly<sub>n</sub>, alkyl of formula -(CH<sub>2</sub>)<sub>n</sub> where n is 3 to 8, preferably 3, 4 or 6, optionally including one or more heteroatoms or unsaturated groups, such as -O- or -S- or -CH=CH- and the like:</p> <p>Lig.b is suitably of the formula Lig.b</p> <p>Lig.b</p>	<p>[0072]</p> <p>[0073]</p>	
---	-----------------------------	--





wherein ring substituents  $X.b^1$  and  $X.b^2$  are independently selected from hydrocarbon such as alkyl

[0075]

or  $SR_x$ ,  $NR_{x2}$  and  $OR_x$  wherein (each)  $R_x$  is selected from  $H$ ,  $C_1$ -alkyl, alkenyl, ring heteroatom  $X.b^3$  is selected from  $-S-$ ,  $-O-$  and  $-CH_2-$ ;

[0076]

$Rb^1$  is selected from saturated or unsaturated, substituted or unsubstituted  $C_{1-4}$  aliphatic, or  $C_{1-3}$  alicyclic optionally including one or more heteroatoms  $N$ ,  $O$ ,  $S$ ,  $P$ , wherein

[0077]

substituent(s) are selected from one or more cycloalkyl, heterocyclic, hydroxy, oxo, halo, amine; preferably  $R.b^1$  comprises a carbonyl substituted by  $H$ , alkyl or a linear or cyclic primary, secondary or tertiary amine, substituted  $C_{1-3}$  alkyl, cycloalkyl or amide, more preferably cyclopropyl, or  $CONHC_{1-3}$ alkyl such as  $CONHEt$  or  $CH_2OH$

[0078]

and each of  $R.b^2$  and  $R.b^3$  is selected from  $H$ , halo, hydroxy, thiol, amine,  $COOH$ ,  $CHO$ , hydrazone, cyano or saturated or unsaturated, substituted or unsubstituted  $C_{1-20}$  branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from  $N$ ,  $O$ ,  $S$ ,  $P$ ,

wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amino, hydrazine, oxo, cyano, and the like, preferably from H, halo or hydroxy, preferably H or Cl;

Rb<sup>4</sup> is H;


[0079]

-L<sub>b</sub> is as hereinbefore defined for -L<sub>a</sub>, more preferably saturated and unsaturated substituted or unsubstituted C<sub>1-12</sub> aliphatic or C<sub>1-24</sub> aromatic as defined for -L<sub>a</sub> preferably including one or more heteroatoms O, S or N, cyclic or heterocyclic groups, more preferably is of formula -L<sub>1</sub>- or -L<sub>2</sub>- as hereinbefore defined, most preferably is -(CH<sub>2</sub>)<sub>m</sub> wherein m is 2 to 12, preferably 3, 4, 6 or 8, or is -(Ph-CH<sub>2</sub>CONH)<sub>2</sub> (CH<sub>2</sub>)<sub>n</sub>:-

[0082]

Lig c is suitably a non-peptide of the formula


Lig c      HOC\*(R,c')CH<sub>2</sub>NH-R.c'-



Where \* indicates an optically active centre and

[0084]

Wherein R<sup>c1</sup> is C<sub>6-14</sub> aryl optionally including one or more heteroatoms selected from H, O, optionally substituted by OH, Hal eg Cl, NH<sub>2</sub>, NHC<sub>1-3</sub>alkyl, sulphonamide, oxoamine (-CONH<sub>2</sub>) and the like, more preferably mono, di or tri substituted phenyl or quinoline wherein substituents include OH, Cl or NH<sub>2</sub>, more preferably m-Cl<sub>2</sub>OH, p-OH phenyl, m-,p-dihydroxy phenol or m-,m-dihydroxyphenol, m-,m-dicl, p-NH<sub>2</sub> phenol, p-OH, m-CONH<sub>2</sub> phenol or 5-OH, 8-quinoline and the like, such as




R<sup>c2</sup> is selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub>, preferably C<sub>1-12</sub>, branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any optionally substituted C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like and combinations thereof,




Preferably R<sup>c2</sup> is selected from C<sub>1-6</sub> branched or straight chain aliphatic, C<sub>6-10</sub> araliphatic

[0085]

[0086]

<p>optionally substituted by OH and optionally including heteroatoms selected from N, O, preferably including an ether O, such as selected from <math>-(CH_2)_6OCH((CH_2)_3Ph)</math>, <math>CHCH_3(CH_2)_3Ph</math>, <math>CHCH_3CH_2PhOH</math>, <math>C(CH_3)_2CH_3</math>;</p> <p>-L- is as hereinbefore defined for -L- and is suitably of formula -L.L- or -L.II- as hereinbefore defined, more preferably is selected from C<sub>1-12</sub> alkyl, amide etc;</p>	<p>[0087]</p>	
<p>Ligd is suitably a non-peptide of the formula</p> <p>Ligd R.d<sup>1</sup> OCH<sub>2</sub>C*HOHCH<sub>2</sub>NH-R.d<sup>2</sup>-#</p>	<p>[0088]</p>	
<p></p> <p>Where * indicates an optically active centre and where # indicates the site of linking to the fluorescent tagging moiety</p>	<p>[0090]</p>	
<p>Wherein R.d<sup>1</sup> is saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional</p>	<p>[0091]</p>	

<p>substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like;</p> <p>Preferably R,d<sup>1</sup> is substituted or unsubstituted C<sub>1-24</sub> aralkyl or heteroaralkyl, including single ring and fused ring systems with (hetero)aryl or cycloalkyl rings, wherein optional substituents include C<sub>1-6</sub> alkyl, alkoxy, ether, carbonyl, alkenyl, amine, amide each optionally carbonyl, amide, halo or OH substituted, or halo such as chloro or OH, preferably R,d<sup>1</sup> is unsubstituted or substituted alkyl, alkenyl, halo, amine, amide, carbonyl, ketone, ether substituted phenyl or naphthyl, illustrated as follows, most preferably mono-, di-, tri- or tetra substituted mono or polycyclic fused aryl or cycloaryl or heterocycloaryl such as phenyl, carbazole or structures shown below or spiro ring systems, most preferably mono-, di-, tri- or tetra alkoxyalkyl, alkoxyalkoxyalkyl or CF<sub>3</sub> substituted phenyl or unsubstituted or monosubstituted naphthalene or 5,6 ring systems most preferably of the structures:</p>	<p>[0092]</p>	
	<p>[0093]</p>	




[0094]

R<sub>4</sub><sup>2</sup>

is substituted or unsubstituted amine, saturated or unsaturated, substituted or unsubstituted C<sub>1-12</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, more preferably amine, C<sub>1-6</sub> branched or straight chain alkyl optionally including ether O, and optionally substituted by C<sub>6-10</sub> aryl, for example of the formula:

<div data-bbox="839 125 922 302" data-label="Chemical-Block"> </div> <div data-bbox="839 388 922 500" data-label="Chemical-Block"> </div> <div data-bbox="730 230 756 848" data-label="Text"> <p>i.pr, i.bu, CH<sub>2</sub>CH<sub>2</sub>O (m-CONH<sub>2</sub>, p-OH) phenol, CH<sub>2</sub>CH<sub>2</sub>O (o-OCH<sub>3</sub>) phenol</p> </div> <div data-bbox="626 111 688 914" data-label="Text"> <p>-L,d- is as hereinbefore defined for -L- and is suitably of formula -L,I- or -L,II- as hereinbefore defined, more preferably is a single bond or is as hereinbefore defined for -L,a-;</p> </div> <div data-bbox="554 111 580 164" data-label="Text"> <p>Lig.e</p> </div> <div data-bbox="481 289 580 914" data-label="Text"> <p>comprises a cell permeant moiety or is associated with a cell permeant L or FI moiety and is suitably of the formula , in either of the following forms given:</p> </div>	<div data-bbox="870 921 896 980" data-label="Text"> <p>[0096]</p> </div> <div data-bbox="341 921 367 980" data-label="Text"> <p>[0098]</p> </div> <div data-bbox="481 921 507 980" data-label="Text"> <p>[0097]</p> </div> <div data-bbox="202 921 227 980" data-label="Text"> <p>[0099]</p> </div>
---	---

Lig.e'



[0100]

wherein

h

is selected from



[0102]



[0103]

[0104]

each optionally substituted by  $R_{e^3} - R_{e^4}$  wherein  $R_{e^1} - R_{e^4}$  are as  $R_{a^1} - R_{a^4}$  defined above or in which  $R_{e^3}$  is  $C_3$  linear or branched alkyl, optionally mono or multi hydroxy or halo substituted or is aryl optionally substituted by alkoxy, sulfonyl and the like eg



<p>ortho-OEt, meta-SO<sub>2</sub>N</p> <p style="text-align: center;">NCH<sub>3</sub></p> <p>each X is independently selected from H, =O, -OR.<sup>e2</sup>, =N, HN, NR.<sup>e3</sup>, HR.<sup>e6</sup>, and aryl optionally substituted by ether; or X is aryl optionally alkyl or alkoxy substituted such as Ph-ortho-OCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;</p>	
<p>and</p> <p>where R.<sup>e3</sup> is as defined above for R.<sup>e1</sup> above or forms a fused cyclic ring together with the adjacent ring N atom; preferably 1 or 2 fused 5 membered cyclic rings;</p> <p>and</p> <p>R.<sup>e6</sup> is as defined above for R.<sup>e1</sup> above or is selected from optionally substituted phenyl wherein optional substituents include ether such as o-ethoxy or o-propoxy, alkyl, OH and the like, sulphonyl, carbonyl and the like substituted by heterocyclic, or cyclic C<sub>3-8</sub> alkyl such as methyl, piperazinyl, sulphonyl and the like;</p>	
<p>or Lig.e is of the formula Lig.<sup>e2</sup></p>	
<p>Lig.<sup>e2</sup></p> <p style="text-align: center;">(h)</p> <p style="text-align: center;">5,6(h)</p>	
<p>Wherein</p> <p>each spiro ring optionally comprises zero or one or more heteroatoms h which are preferably N, more preferably</p> <p style="text-align: center;">(h)</p> <p style="text-align: center;">comprises zero or</p>	

1 N heteroatom and	5,6(h) comprises zero, 1 or 2 N	
<p>heteroatoms and is unsaturated or comprises one or two -C=C- or -C=N- groups, and wherein each ring is optionally substituted by one or more oxo, CO, COOH, C<sub>1-6</sub> alkyl or linear or cyclic alkoxy such as methoxy, ethoxy or cyclopropyloxy optionally substituted by one or more oxo, CO, COOH, CN, or C<sub>1-6</sub> alicyclic or amine groups, amine or one or more spiro or fused heterocycles,</p>		
<p>or Lig e is of the formula Lig e<sup>3</sup></p>		
<p>R<sub>e</sub><sup>11</sup></p>		
<p>R<sub>e</sub><sup>11</sup></p>		
<p>Lig e<sup>3</sup></p>		
<p>C<sub>E1</sub></p>		
<p>C<sub>E2</sub></p>		
<p>R<sub>e</sub><sup>12</sup></p>		
<p>Wherein each of C<sub>E1</sub> and C<sub>E2</sub> is independently selected from aryl, heteroaryl, cycloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group;</p>		
<p>Each of up to seven R<sub>e</sub><sup>11</sup> is a substituent of a ring carbon or a ring heteroatom and: is independently selected from saturated or unsaturated, substituted or unsubstituted C<sub>1-20</sub> branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of</p>		

which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C<sub>1-12</sub> aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, such as =O, OCH<sub>3</sub>, CH<sub>2</sub>Ph(OCH<sub>3</sub>)<sub>2</sub>, O(CH<sub>2</sub>)<sub>2</sub>CON(CH<sub>3</sub>)<sub>2</sub>hex, N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, chex, COOCH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>; any two or more of R.e<sup>11</sup> form a one, two or three ring fused cyclic structure, preferably comprising a fused 3 ring aryl, 5-heterocyclic, 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.e<sup>3</sup> structure; and R.e<sup>12</sup> is a moiety as defined for R.e<sup>11</sup> above;

Preferably Lig.e is of the formula Lig.e<sup>1</sup> as hereinbefore defined in particular where R.e<sup>2</sup> and R.e<sup>3</sup> are respectively propyl and butyl;

-L.e- is suitably as hereinbefore defined for -L.a-

96. (new). Compound as claimed in claim 95 wherein FI is selected from the following dyes: Texas red™, coumarin and derivatives, Cascade Blue™, EyoBlue and fluorescent derivatives thereof, pyrenes and pyridylloxazole derivatives, the cyanine dyes, the dymics (DY dyes and ATTO dyes) and fluorescent derivatives thereof, the Alexafluor dyes and derivatives, BDI dyes

[0115]

<p>including the commercially available Bodipy™ dyes, pyrenes, anthracenes, acridines, fluorescent phycoobiliproteins and their conjugates and fluoresceinated microbeads, and Texas Red derivatives, coupled to amine groups using the isocyanate, succinimide ester or dichlorotriazinyl- reactive groups.</p>		
<p>97 (new and withdrawn). Process for the preparation of a library as claimed in Claim 59, wherein reactive groups <math>Y_{Lig}</math>, <math>Y_L</math>, <math>Y_T</math> have suitable reactive group functionalities for linking by addition or addition – elimination reaction.</p>	<p>[0134]</p>	
<p>98 (new and withdrawn). Process for the preparation of a compound as claimed in Claim 60, wherein reactive groups <math>Y_{Lig}</math>, <math>Y_L</math>, <math>Y_T</math> have suitable reactive group functionalities for linking by addition or addition – elimination reaction.</p>	<p>[0134]</p>	